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A B S T R A C T
Background
People with asthma have a higher prevalence of anxiety and depression than the general population. This is associated with poorer
asthma control, medication adherence, and health outcomes. Cognitive behavioural therapy (CBT) may be a way to improve the quality
of life of people with asthma by addressing associated psychological issues, which may lead to a lower risk of exacerbations and better
asthma control.
Objectives
To assess the efficacy of CBT for asthma compared with usual care.
Search methods
We searched the Cochrane Airways Group Specialised Register, ClinicalTrials.gov, and the World Health Organization International
Clinical Trials Registry Platform (WHO ICTRP).We also searched reference lists of all primary studies and review articles and contacted
authors for unpublished data. The most recent searches were conducted in August 2016.
Selection criteria
We included parallel randomised controlled trials (RCTs) comparing any cognitive behavioural intervention to usual care or no
intervention. We included studies of adults or adolescents with asthma, with or without comorbid anxiety or depression. We included
studies reported as full text, those published as abstract only, and unpublished data.
Data collection and analysis
Two or more review authors independently screened the search results, extracted data, and assessed included studies for risk of bias.
We analysed dichotomous data as odds ratios (ORs) and continuous data as mean differences (MDs) or standardised mean differences
(SMD) where scales varied across studies, all using a random-effects model. The primary outcomes were asthma-related quality of life
and exacerbations requiring at least a course of oral steroids. We rated all outcomes using GRADE and presented our confidence in the
results in a ’Summary of findings’ table.
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Main results
We included nine RCTs involving 407 adults with asthma in this review; no studies included adolescents under 18. Study size ranged
from 10 to 94 (median 40), and mean age ranged from 39 to 53. Study populations generally had persistent asthma, but severity and
diagnostic measures varied. Three studies recruited participants with psychological symptomatology, although with different criteria.
Interventions ranged from 4 to 15 sessions, and primary measurements were taken at a mean of 3 months (range 1.2 to 12 months).
Participants given CBT had improved scores on the AsthmaQuality of Life Questionnaire (AQLQ) (MD0.55, 95% confidence interval
(CI) 0.17 to 0.93; participants = 214; studies = 6; I2 = 53%) and on measures of asthma control (SMD -0.98, 95% CI -1.76 to -0.20;
participants = 95; studies = 3; I2 = 68%) compared to people getting usual care. The AQLQ effect appeared to be sustained up to a
year after treatment, but due to its low quality this evidence must be interpreted with caution. As asthma exacerbations requiring at
least a course of oral steroids were not consistently reported, we could not perform a meta-analysis.
Anxiety scores were difficult to pool but showed a benefit of CBT compared with usual care (SMD -0.38, 95% CI -0.73 to -0.03),
although this depended on the analysis used. The confidence intervals for the effect on depression scales included no difference between
CBT and usual care when measured as change from baseline (SMD -0.33, 95% CI -0.70 to 0.05) or endpoint scores (SMD -0.41,
95% CI -0.87 to 0.05); the same was true for medication adherence (MD -1.40, 95% CI -2.94 to 0.14; participants = 23; studies = 1;
I2 = 0%).
Subgroup analyses conducted on the AQLQ outcome did not suggest a clear difference between individual and group CBT, baseline
psychological status, or CBT model. The small number of studies and the variation between their designs, populations, and other
intervention characteristics limited the conclusions that could be drawn about these possibly moderating factors.
The inability to blind participants and investigators to group allocation introduced significant potential bias, and overall we had low
confidence in the evidence.
Authors’ conclusions
For adults with persistent asthma, CBT may improve quality of life, asthma control, and anxiety levels compared with usual care. Risks
of bias, imprecision of effects, and inconsistency between results reduced our confidence in the results to low, and evidence was lacking
regarding the effect of CBT on asthma exacerbations, unscheduled contacts, depression, and medication adherence. There was much
variation between studies in how CBT was delivered and what constituted usual care, meaning the most optimal method of CBT
delivery, format, and target population requires further investigation. There is currently no evidence for the use of CBT in adolescents
with asthma.
P L A I N L A N G U A G E S U M M A R Y
Cognitive behavioural therapy for people with asthma
Take-home message
Cognitive behavioural therapy (CBT) may improve the quality of life and asthma control of adults with asthma, but there is limited
evidence for other important outcomes, and our confidence in the results is quite low. None of the studies included adolescents with
asthma.
Review question
We wanted to review the evidence of the effect of CBT compared to usual care (without CBT) on a range of health outcomes in people
with asthma including quality of life, medication adherence, and levels of anxiety and depression.
Background
People with asthma suffer from anxiety and depression more than the general public. These psychological problems are linked with
having worse asthma, including having poorer control of symptoms and being admitted to hospital more often. CBT is a talking
therapy that aims to help people recognise how their behaviour affects their thoughts and feelings, which may help people with asthma
better cope with their condition. We wanted to learn whether using CBT was better than not using CBT for improving the lives of
people with asthma.
Study characteristics
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The evidence reviewed is current to August 2016. We included nine studies with a total of 407 participants in the review. All of the
participants had asthma. In three of the nine studies, the participants also had a diagnosis of anxiety or depression, or both. The CBT
was given either individually or in a group and ranged from four to 15 sessions.
Key results
Participants given CBT had improved scores on the Asthma Quality of Life Questionnaire (AQLQ) and on measures of asthma control
compared to participants who did not receive CBT. The studies generally did not report whether CBT reduced the likelihood of people
needing oral steroids for an asthma attack. The benefit on AQLQ score was sustained up to a year after receiving CBT. Participants
given CBT also had better anxiety scores compared to those given usual care. Participants given CBT did not have clearly improved
depression scale scores or medication adherence.
The overall quality of evidence presented is low due to the small number of studies included in the review, the differences in the design
of the studies and in how the CBT was conducted, and because the participants knew to which treatment group (CBT or no CBT)
they had been assigned.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Cognitive behavioural therapy (CBT) for adults and adolescents with asthma
Patient or population: adults and adolescents with asthma
Setting: outpat ient care
Intervention: CBT
Comparison: usual care (some variat ion in control group def init ions among studies such as ‘‘no treatment’’, ‘‘wait ing list ’’)
The weighted mean outcome assessment was taken at 3.3 months (range 1.2 to 12 months).
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with usual care* * Risk with CBT
Asthma- related quality
of life (AQLQ)
1 to 7 scale
(higher scores better)
The mean change in
AQLQ score in the usual
care group was 0.53.
The mean AQLQ score
in the intervent ion
group was 0.55 better
(0.17 better to 0.93 bet-
ter).
- 214
(6 RCTs)
⊕⊕©©
LOW 12
Benef it of CBT over
usual care
The MCID on the AQLQ
is 0.5 units.
Asthma exacerbations
requiring at least a
course of oral steroids
Analysis not possible due to inconsistent def ini-
t ions, baseline imbalances, and incomplete diary
data
- - Not graded Results are reported
narrat ively in the re-
view.
Asthma control
Mean change on the
ASC and ACQ
(adjusted so lower
scores are better)
It was not possible
to derive a meaningful
control group risk be-
cause dif ferent scales
were used
The mean asthma con-
trol in the intervent ion
group was 0.98 stan-
dard deviat ions better
(1.76 better to 0.2 bet-
ter).
- 95
(3 RCTs)
⊕⊕©©
LOW 134
Benef it of CBT over
usual care, but signif i-
cant variat ion in results
Unscheduled health-
care visits
Mean visits per part ic-
ipant in the 6 months
af ter treatment
(lower scores better)
The usual care group
had a mean 2.08 GP
visits.
There were 0.28 fewer
unscheduled GP vis-
its in the intervent ion
group (1.36 fewer to 0.
8 more)
- 80
(1 RCT)
⊕⊕©©
LOW 56
No evidence of a ben-
ef it of CBT over usual
care.
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Primary care visits in-
cluded nurse and out-
of -hours visits
The usual care group
had a mean 2.27 pri-
mary care visits.
There were 0.40 fewer
unscheduled primary
care visits in the in-
tervent ion group (1.51
fewer to 0.71 more)
Anxiety scales
Mean change on the
ASC panic/ fear, PSS,
and HADS-Anxiety
(lower scores better)
It was not possible
to derive a meaningful
control group risk be-
cause dif ferent scales
were used
The mean change in the
intervent ion group was
0.38 standard devia-
tions better (0.73 bet-
ter to 0.03 better)
- 225
(4 RCTs)
⊕⊕©©
LOW 1789
Possible small benef it
of CBT over usual care
Our conf idence was re-
duced by a smaller and
less precise result f rom
3 more studies (n =
142) report ing endpoint
scores (SMD -0.25, 95%
CI -1.02 to 0.51)
Depression scales
Mean change on HADS-
Depression.
Endpoint scores on
NEM, BDI, and QD (see
comment)
(lower scores better)
The usual care group
showed a mean change
on the HADS-Depres-
sion of - 1.7 units.
The mean change in the
intervent ion group was
0.33 standard devia-
tions better (0.70 bet-
ter to 0.05 worse).
- 112
(2 RCTs)
⊕⊕©©
LOW 191011
Possible small bene-
f it of CBT over usual
care, but conf idence in-
tervals include no dif -
ference
3 more studies (n
= 83) report ing end-
point scores on various
scales showed a sim ilar
result (SMD -0.41, 95%
CI -0.87 to 0.05)
M edication adherence
6-item Adherence Scale
rated 1 to 5 (lower
scores better)
The mean medicat ion
adherence in the usual
care group was 8.4.
The mean medicat ion
adherence in the inter-
vent ion group was 1.4
units better (2.94 bet-
ter to 0.14 worse).
- 23
(1 RCT)
⊕⊕©©
LOW 12
Possible small bene-
f it of CBT over usual
care, but conf idence in-
tervals include no dif -
ference5
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
* * The risk in the control group is based on the usual care scores in each study contribut ing to the analysis. For cont inuous outcomes, this could not include studies report ing
mean dif ference between groups.
ACQ: Asthma Control Quest ionnaire; AQLQ: Asthma Quality of Life Quest ionnaire; ASC: Asthma Symptom Checklist ; BDI: Beck Depression Inventory; CI: conf idence interval;
GP: general pract it ioner (family doctor); HADS: Hospital Anxiety and Depression Scale; M CID: m inimal clinically important dif f erence; M D: mean dif ference; NEM : Negat ive
Emotionality Scale; PSS: Perceived Stress Scale; QD: Depression Quest ionnaire (in Italian); RCT : randomised controlled trial; SM D: standardised mean dif ference
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1These subject ive rat ing scales may have been biased by the inability to blind part icipants and personnel to group assignment.
Addit ionally, some studies contribut ing to the ef fect were at high risk of bias due to high or unbalanced dropout (-1 risk of
bias).
2There was important variat ion between the study results (I2 = 53%, P = 0.06) (-1 inconsistency).
3There was important variat ion between the study results (I2 = 68%, P = 0.04) (-1 inconsistency).
4The ef fect is based on small numbers of studies and part icipants randomised, but we did not consider this a suf f icient
reason to downgrade (no downgrade for imprecision).
5The study was at high risk of performance bias, but it is unclear whether this would have af fected the behaviour of part icipants
for this outcome, or the way it was recorded by study personnel. The study was also rated high risk for attrit ion bias, but we
did not consider this suf f icient to warrant a downgrade (no downgrade for risk of bias).
6Only one study with 80 part icipants reported the outcome, and the conf idence intervals for the ef fect made it dif f icult to tell
whether CBT is likely to have any benef it over usual care (-2 imprecision).
7Stat ist ical heterogeneity in the change scores was not signif icant (I2 = 28%, P = 0.25), but there was much variat ion between
the endpoint scores shown in the comments for this outcome (I2 = 76%, P = 0.01) and inconsistency between the two analyses
(-1 inconsistency).
8The ef fect based on change scores was relat ively precise, but the endpoint scores analysis was not (no downgrade for
imprecision).
9Deshmukh 2008 measured the HADS-Anxiety and HADS-Depression, the results of which were not available in the abstract
or poster, but the number of part icipants (n = 12) means the results are unlikely to have been af fected (no downgrade for
publicat ion bias).
10The conf idence intervals did not exclude no dif ference so it is dif f icult to tell whether CBT has an important ef fect on
depression (-1 imprecision).
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11Stat ist ical heterogeneity was very high in the analysis of endpoint scores shown in the comments for this outcome (I2 =
80%, P = 0.007), but there was no important variat ion in the change scores analysis (I2 = 0%, P = 0.58) or between the two
depression analyses (no downgrade for inconsistency).
12Only one study with 23 part icipants reported the outcome, and the conf idence intervals for the ef fect did not exclude no
dif ference between CBT and usual care (-2 imprecision).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Asthma is a chronic disease of the airways that causes reversible
breathing difficulties due to narrowing of the airways, thicken-
ing of the airway walls, and increased mucus production (GINA
2016). These physical characteristics commonly lead to symp-
toms including wheezing, shortness of breath, chest tightness, and
cough, which vary significantly over time and between people
(GINA 2016).
Recent estimates suggest that over 334 million people have asthma
worldwide, which leads to direct treatment costs and indirect costs
to society that are amongst the highest for non-communicable
diseases (Global Asthma Network 2014). The disease is a signif-
icant cause of avoidable morbidity and mortality in high-income
countries such as the UK and Australia for patients, their families,
and in terms of lost working days (GINA 2016; Global Asthma
Network 2014; Royal College of Physicians 2014), and evenmore
so in low- and middle-income countries, where it often goes un-
diagnosed and untreated (Global Asthma Network 2014).
People with asthma have a higher prevalence of anxiety and depres-
sion than the general population (GINA 2016; Zielinski 2000).
Depending on the severity of asthma, prevalence of depression has
been estimated at between 22% and 45%, and anxiety and panic
disorder between 6.5% and 26% (Ettinger 2004; Heaney 2005;
Katon 2004; Lavoie 2010; Mancuso 2000). Asthma symptoms
canworsen quickly during exacerbations and are often frightening,
especially for young people (BTS/SIGN 2014). This can lead to
health-related anxiety and hypervigilance, which can act as a future
trigger for asthma (Thoren 2000).Whether asthma causes anxiety
and depression, or the psychological disorder precedes an asthma
diagnosis, the two can influence each other and make both condi-
tions more difficult to live with (Asthma UK 2015). Adolescents
with asthma in particular are at a greater risk of major depression,
panic attacks, and anxiety disorders, which have been associated
with an increased burden of asthma symptoms and inability to
cope with the disease (Richardson 2006). The presence of psycho-
logical disorders in people with asthma of any age is associated
with poorer asthma outcomes and increased hospital utilisation
(GINA 2016), particularly for those from disadvantaged socio-
economic and ethnic backgrounds (Royal College of Physicians
2014).
In asthma, the increased incidence of anxiety and panic disorders
in particular is complicated by their overlap in symptoms (Carr
1998; Shavitt 1992), which can mean symptoms of anxiety are of-
tenmisinterpreted by patients and clinicians (Avner 1988). Symp-
toms that are common to both conditions include breathlessness,
chest tightness, psychogenic cough, palpitations, and inability to
complete sentences (Asthma UK 2015; BTS/SIGN 2014). This
overlap, and general feelings of not being able to cope, can lead
to overuse of bronchodilators, which are associated with serious
side effects (FDA 2010). Conversely, depression in asthma can
lead to poor adherence with preventative medications and non-
adherence to lifestyle advice (e.g. smoking cessation, recreational
drug use, and allergen avoidance), which may increase the likeli-
hood of exacerbations and loss of asthma control (Royal College
of Physicians 2014).
Description of the intervention
Cognitive behavioural therapy (CBT) is a form of talking ther-
apy that explores a person’s perceptions of themselves and others
and how a person’s behaviour influences their thoughts and feel-
ings. CBT aims to positively change how a person thinks (‘cogni-
tive’) and what they do (‘behaviour’). CBT entails psychological
analysis of a specific problem or situation. The specific thoughts,
emotions, physical feelings, and actions that relate to this specific
problem are explored. A more positive way of thinking about the
specific situation or problem is developed and a more helpful be-
havioural response is aimed for. There are different models and
methods of delivering CBT. The classic model of CBT (or so-
called second-wave CBT) has a strong focus on addressing sim-
ple information processing. It has traditionally been delivered face
to face either individually or in a group. Online models, which
are cheaper to deliver and more accessible for patients, also exist
but may be less effective than face-to-face therapy (Mayo-Wilson
2013). Newer ‘third-wave CBT’ includes a more heterogeneous
group of treatments including mindfulness, dialectical-based ther-
apy, behavioural activation, and schema therapy, among others.
Cognitive behavioural therapy has a large evidence base and is ef-
fective for a range of psychological disorders, which has resulted in
it being recommended in a range of treatment guidelines (e.g. de-
pression, generalised anxiety disorder, social anxiety) (NICE 2009;
NICE 2011; NICE 2013). Most research into CBT focuses on
people with mental health problems, but evidence is growing to
support its use in chronic illness, especially as part of self manage-
ment plans, to help people cope with the psychological aspects of
physical illness. These include worrying and painful symptoms,
demanding and debilitating treatments and their side effects, fa-
tigue, and lifestyle change (White 2001). CBT has been used in
this way for asthma as a way of encouraging patients to accept their
problems, keep control of their symptoms and medications, and
alleviate anxiety related to their condition (Grover 2002; Kotses
1995).
Therapies vary in the specific components used and in the deliv-
ery and duration of treatment. They are usually based on a struc-
tured manual that can be adapted according to the individual’s
particular problems, and can be delivered for between 5 and 20
weekly or fortnightly sessions of 30 to 60 minutes (Royal College
of Psychiatrists 2015).
8Cognitive behavioural therapy (CBT) for adults and adolescents with asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How the intervention might work
Cognitive behavioural therapy is “a way of talking about how
you think about yourself, the world and other people [and] how
what you do affects your thoughts and feelings” (Royal College of
Psychiatrists 2015). In the context of chronic diseases, a person
might find certain aspects of their disease worrying or difficult to
deal with. In some situations this might be realistic, but the extent
of worry, panic, or sadness may be exaggerated compared with the
actual threat, and may cause them to behave differently (avoiding
certain activities, taking too much medication). This in turn leads
to physiological responses that are misinterpreted to reinforce and
maintain their unhelpful behaviours and fears (Figure 1). CBT
aims to break this cycle by encouraging people to challenge their
unhelpful thoughts and form more realistic ones based on what
is more likely to happen, and confront situations or activities that
worry them.
Figure 1. Cycle of worry in asthma.
Why it is important to do this review
The psychological aspects of asthma are associated with increased
morbidity and mortality, which may be partially explained by an
association between depression and anxiety and poor adherence
with medicines (DiMatteo 2000). In asthma, poor psychological
well-being has been associated with an increased burden of asthma
symptoms and poor self management, which places greater pres-
sure on health services (GINA 2016; Richardson 2006). It is im-
portant to assess the effect of CBT on quality of life to determine
whether the treatment can help people to better cope with these
psychological and asthma-related difficulties. We also examined
whether CBT has the potential to improve clinical asthma symp-
toms, particularly the likelihood of needing oral steroids to treat
exacerbations, whichmay result from encouraging better self man-
agement and treatment adherence, and improving psychological
well-being.
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A Cochrane systematic review of all psychological therapies for
asthma published in 2006 was unable to draw any definitive con-
clusions regarding the effectiveness of these treatments due to vari-
ation in the interventions, small trials, and inadequate reporting
(Yorke 2006). This review summarised the updated evidence base,
focusing on the usefulness of the most widely used and studied
psychological intervention, CBT, on an updated set of outcomes.
O B J E C T I V E S
To assess the efficacy of CBT for asthma compared with usual care.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel randomised controlled trials (RCTs) of any
duration. We excluded trials with a cross-over design because it
is unlikely that the effects of the intervention could be effectively
’washed out’ between treatment periods. Due to the nature of the
interventions, we anticipated that the studies would be unblinded
for participants and personnel, but we included studies irrespective
of whether they blinded outcome assessors. We included studies
reported as full text, those published as abstract only, and unpub-
lished data.
Types of participants
We included studies of adults and adolescents from 12 years of age
with a diagnosis of asthma according to internationally recognised
guidelines, for example GINA 2016. Participants did not have to
have a clinical diagnosis of anxiety or depression to be included.
If studies included younger children, we included the study if the
mean age of the study population was above 12. We excluded
studies ofmixedpopulations (i.e. those recruiting participantswith
chronic obstructive pulmonary disease (COPD) or other chronic
conditions) unless results for people with asthma were presented
separately.
Types of interventions
We included studies comparing individual or group CBT with
usual care or minimal-intervention control groups. Relevant ther-
apies included both cognitive and behavioural elements which had
a specific focus on tackling negative thoughts and behaviours re-
lating to asthma. We included any model of CBT including ac-
ceptance and mindfulness-based therapies. We included studies
that allowed any asthma medications or co-interventions as long
as theywere the same for both groups.We included control groups
on a waiting list as long as they continued to receive usual asthma
care, and minimal-intervention control groups such as the use of
printed materials.
Types of outcome measures
Primary outcomes
1. Asthma-related quality of life (measured on a validated
scale, e.g. Asthma Quality of Life Questionnaire (AQLQ))
2. Asthma exacerbations requiring at least a course of oral
steroids
i) Due to the variation in reporting of asthma
exacerbations, we also considered data for other types of
unscheduled healthcare utilisation depending on what was
available.
Quality of life is an important outcome that can reflect to what
degree asthma affects people’s lives. Cognitive behavioural therapy
may result in better symptom control by improving adherence
and reducing the negative effects of anxiety and depression, but
may also help people to accept and deal with symptoms better
when they do arise. Looking at asthma exacerbations allowed us
to assess whether any positive effect of CBT leads to important
clinical benefits.
Secondary outcomes
1. Asthma control (measured on a validated scale, e.g. Asthma
Control Questionnaire (ACQ))
2. Unscheduled contacts with health services for asthma (i.e.
emergency general practitioner appointment, emergency
department visit, or hospitalisation)
3. Validated scales of anxiety
4. Validated scales of depression
5. Medication adherence
We did not anticipate ’adverse events’ being defined or recorded
as they would be in drug studies, but rather as negative events
relating to asthma which will fall within ’asthma exacerbations
requiring at least a course of oral steroids’ or ’unscheduled contacts
with health services for asthma’. In this sense, the direction of the
effect indicated benefit or potential harm of CBT compared with
the control group. If other adverse events were reported that did
not fall under these categories, we described them narratively.
Reporting one or more of the outcomes listed here in the study
was not an inclusion criterion for the review.
If different scales measuring the same outcome were used across
studies, we pooled them in the same analysis using standardised
mean differences if we judged this to be appropriate.
The main time point for measurement was after the CBT inter-
vention had been completed, and we looked at information for
long-term follow-up separately if it was available.
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Search methods for identification of studies
Electronic searches
We identified studies from the Cochrane Airways Group Spe-
cialised Register, which is maintained by the Information Special-
ist for the Group. The Register contains trial reports identified
through systematic searches of multiple bibliographic databases
and handsearching of respiratory journals and meeting abstracts
(Appendix 1). We searched all records in the Cochrane Airways
Group Specialised Register using the search strategy illustrated in
Appendix 2.
We also conducted
a search of ClinicalTrials.gov (clinicaltrials.gov/) and the World
Health Organization International Clinical Trials Registry Plat-
form (WHO ICTRP) (apps.who.int/trialsearch/).We searched all
databases from their inception to August 2016 with no restriction
on language of publication.
Searching other resources
We checked reference lists of all primary studies and review articles
for additional references.We contacted authors of included studies
regarding ongoing or unpublished trials.
We searched for errata or retractions from included studies pub-
lished in full on PubMed on 29 January 2016.
Data collection and analysis
Selection of studies
Two review authors (KK andMN or VD) independently screened
titles and abstracts of all the potential studies we identified as a
result of the search and coded them as ’retrieve’ (eligible or poten-
tially eligible/unclear) or ’do not retrieve’. We retrieved the full-
text study reports/publications, and two review authors (KK and
MN or VD) independently screened the full text and identified
studies for inclusion, and identified and recorded reasons for ex-
clusion of the ineligible studies. We resolved any disagreements
through discussion or, if required, by consulting a third review au-
thor (MN or VD, whoever had not already screened the record).
We identified and excluded duplicates and collated multiple re-
ports of the same study so that each study, rather than each report,
was the unit of interest in the review. We recorded the selection
process in sufficient detail to complete a PRISMA flow diagram
and Characteristics of excluded studies table (Moher 2009).
Data extraction and management
We used a data collection form for study characteristics and out-
come data that was piloted on at least one study in the review.
Two review authors (KK and MN or VD) extracted the following
study characteristics from the included studies.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (KK and MN or VD) independently ex-
tracted outcome data from the included studies. We noted in the
Characteristics of included studies table if outcome data were not
reported in a usable way. We resolved disagreements by consensus
or by involving a third review author (either MD or VD, whoever
had not already extracted data). One review author (KK) trans-
ferred data into Cochrane statistical software (Review Manager
2014). We double-checked that data were entered correctly by
comparing the data presented in the systematic review with the
study reports.
Assessment of risk of bias in included studies
Two review authors (KK and MN or VD) independently assessed
risk of bias for each study using the criteria outlined in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreements by discussion or by involving a
third review author (either MD or VD, whoever had not already
extracted data).
We assessed the risk of bias according to the following domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting;
7. other bias.
We graded each potential source of bias as high, low, or unclear
and provided a quote from the study report together with a jus-
tification for our judgement in the ’Risk of bias’ table. We sum-
marised the ’Risk of bias’ judgements across different studies for
each of the domains listed. We considered blinding separately for
different key outcomes where necessary (e.g. for unblinded out-
come assessment, risk of bias for all-cause mortality may be very
different than for a patient-reported pain scale). Where informa-
11Cognitive behavioural therapy (CBT) for adults and adolescents with asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
tion on risk of bias related to unpublished data or correspondence
with a trialist, we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for the studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to the published protocol,
Kew 2015, and reported any deviations from it in the Differences
between protocol and review section of the systematic review.
Measures of treatment effect
We analysed dichotomous data as odds ratios and continuous data
as mean differences or standardised mean differences. We entered
data presented as a scale with a consistent direction of effect.
We undertook meta-analyses only where this was meaningful, that
is if the treatments, participants, and the underlying clinical ques-
tion were similar enough for pooling to make sense.
We described skewed data reported as medians and interquartile
ranges narratively.
Where multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms. If two comparisons (e.g. drug A
versus placebo and drug B versus placebo) were combined in the
same meta-analysis, we halved the control group to avoid double-
counting.
Unit of analysis issues
For dichotomous outcomes, we used participants rather than
events as the unit of analysis (i.e. number of adults admitted to
hospital rather than number of admissions per adult). However,
if exacerbations were reported as rate ratios, we analysed them on
this basis.
Dealing with missing data
We contacted investigators or study sponsors in order to verify
key study characteristics and to obtain missing numerical outcome
data where possible (e.g. when we identified a study as abstract
only). Where this was not possible, and the missing data were
thought to introduce serious bias, we explored the impact of in-
cluding such studies in the overall assessment of results by a sen-
sitivity analysis.
Assessment of heterogeneity
We used the I2 statistic and visual inspection of the forest plots to
measure heterogeneity among the studies in each analysis. If we
identified substantial heterogeneity, we reported it and explored
possible causes by prespecified subgroup analysis.
Assessment of reporting biases
As we were unable to pool more than 10 studies, we could not
create and examine a funnel plot to explore possible small-study
and publication biases as planned in the protocol.
Data synthesis
We used a random-effects model for all analyses, as we expected
variation in effects due to differences in study populations and
methods. We performed sensitivity analyses with a fixed-effect
model.
’Summary of findings’ table
We created a ’Summary of findings’ table presenting data for
all prespecified outcomes (Summary of findings for the main
comparison).Weused the five GRADE considerations (study lim-
itations, consistency of effect, imprecision, indirectness, and pub-
lication bias) to assess the quality of a body of evidence as it re-
lates to the studies that contribute data to the meta-analyses for
the prespecified outcomes. We used methods and recommenda-
tions described in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011), utilising GRADEpro software
(GRADEpro GDT 2016). We justified all decisions to down- or
upgrade the quality of studies using footnotes, and we made com-
ments to aid the reader’s understanding of the review where nec-
essary.
Subgroup analysis and investigation of heterogeneity
We planned the following subgroup analyses for the primary out-
comes:
1. individual versus group CBT;
2. mean age (18 years and younger versus older than 18 years);
3. baseline psychological symptoms (populations required to
meet criteria for anxiety or depression versus populations with
subclinical symptoms);
4. types of CBT (e.g. classic versus newer models)*.
We used the formal test for subgroup interactions in Review
Manager 2014.
*We included third-wave cognitive behavioural approaches in the
scope of this review, but recognise that there are differences be-
tween these models and classic CBT, particularly in the way un-
helpful thoughts are dealt with, which may lead to different out-
comes.
In Table 1 we have presented key characteristics of the study pop-
ulations and interventions to display other potential sources of
heterogeneity that may not be easily assessed in subgroups (e.g.
measures of asthma severity, concomitant use of asthma and psy-
chotropic medications, frequency and duration of CBT sessions).
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Sensitivity analysis
We planned the following sensitivity analyses:
1. studies at high risk of bias for blinding of outcome assessors;
2. unpublished data (from conference abstracts or obtained
from authors).
R E S U L T S
Description of studies
Results of the search
We identified 740 records through database searching and 24 ad-
ditional records by searching theWHO trials portal (n = 9), Clin-
icalTrials.gov (n = 13), and reference lists of included studies and
existing systematic reviews (n = 4). We removed four duplicates,
and screened the titles and abstracts of the remaining 760 unique
records for inclusion. We excluded 701 on the basis of the titles
and abstracts alone, and retrieved full papers for the remaining
59. Upon closer inspection of the papers, we found that 42 did
not meet the inclusion criteria for the review (reasons given in
Excluded studies and Figure 2), and recorded three of the records
retrieved from trial registries as ongoing studies. We have included
nine studies with 14 associated citations in the review, eight of
which contributed to at least one meta-analysis.
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Figure 2. Study flow diagram.
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Included studies
We identified nine studies (including 407 participants) that met
the inclusion criteria for this review, with a total of 14 associated
publications or reports. All of the studies were considered to be
randomised controlled trials, although in some of the older trials
the methods of selection and allocation were less clearly described.
The studies were published between 1995 and 2013; two were
only available as conference abstracts at the time of the writing
of this review (Deshmukh 2008; Grover 2002). The studies were
all relatively small, with a population size ranging from 10 to 94
(median 40). Four studies were conducted in Europe (Parry 2012;
Put 2003; Sommaruga 1995; Yorke 2013), two in North America
(Pbert 2012; Ross 2005), two in India by the same research team
(Grover 2002; Grover 2007), and one in Australia (Deshmukh
2008). A summary of study characteristics is presented in Table 1,
and more detailed descriptions are available in the Characteristics
of included studies tables.
Participants
All studies recruited participants with asthma, either according to
a physician’s judgement or guideline-defined criteria. Grover 2007
required a diagnosis for at least two years, and Put 2003 for six
months with recent symptoms. Pbert 2012 required participants
to meet criteria for mild, moderate, or severe persistent asthma
according to National Institutes of Health/National Heart, Lung,
and Blood Institute (NIH/NHBLI) criteria. Ross 2005 and Yorke
2013 set criteria to recruit a more severe population, the former
by requiring a referral to a pulmonary specialist and a recent emer-
gency department visit for an exacerbation, and the latter by spec-
ifying that participants should meet criteria for severe refractory
asthma (ATS 2000), and by recruiting participants from national
specialist severe asthma clinics.
Three studies specifically recruited participants with psychological
symptoms, althoughwith very different criteria (Deshmukh 2008;
Parry 2012; Yorke 2013). Deshmukh 2008 required “comorbid
anxiety and asthma”; Parry 2012 and Yorke 2013 recruited people
whomet cutoffs on a psychological symptom scale; and Ross 2005
specifically recruited people with asthma and a primary diagnosis
of panic disorder. Some studies excluded people with severe psy-
chiatric illness (Parry 2012; Ross 2005; Yorke 2013), and others
for a history of psychological illness requiring current or past use
of psychotropic medication (Grover 2007; Parry 2012), a recent
dose change (Ross 2005; Yorke 2013), or previous participation
in a psychological or an educational intervention (Grover 2007;
Parry 2012; Put 2003).
Studies specifying age recruited adults over 18, andmean age of the
randomised populations ranged from 39.0 to 52.7. Most studies
excluded some medical comorbidities, usually including at least
other respiratory illnesses, but often cardiovascular disease and
drug, alcohol, or nicotine dependence. No studies mentioned re-
cruiting adolescents under the age of 18.
Minimal information about baseline characteristics or inclusion
and exclusion criteria was available for Deshmukh 2008, Grover
2002, and Sommaruga 1995.
Interventions and comparisons
As per the eligibility criteria for this review, all of the studies tested
a psychological intervention including cognitive and behavioural
elements, although these varied in nature, duration, and delivery.
Eight studies used a classic model of CBT (five individual, two
group, and one unclear), and one used a group mindfulness-based
model (Pbert 2012). Where they were described, specific compo-
nents of classic CBT could usually be categorised under asthma
education, psycho-education, relaxation or breathing techniques,
cognitive restructuring, problem-solving, and coping skills. Four
studies did not describe the qualifications of those delivering the
intervention (Deshmukh 2008; Grover 2002; Grover 2007; Pbert
2012). In the other five studies, the intervention was delivered by
trained clinical psychologists (Put 2003; Sommaruga 1995; Yorke
2013), doctoral nurse clinicians (one trained in CBT and one as
an asthma educator) (Ross 2005), or amix of trained psychologists
and a cognitive behavioural therapist (Parry 2012).
Six studies provided one-on-one sessions of classic CBT (Grover
2002; Grover 2007; Parry 2012; Put 2003; Sommaruga 1995);
Grover 2002 and Grover 2007 both tested a 15-session individual
CBT program, although the earlier study used a standard phar-
macotherapy control group, and the later one tested CBT on top
of an asthma self management program compared to self manage-
ment alone. The intervention in Parry 2012 consisted of 4 to 6
individual sessions over 6 to 13weeks plus an introductory session,
compared with a no-treatment control group who were offered the
intervention at the end of the study. Put 2003 gave six one-hour
individual sessions of classic CBT compared with a waitlist control
group. The intervention in Sommaruga 1995 was described as an
“Asthma Rehabilitation Group”, which included three individual
sessions of CBT as well as an educational programme, telephone
access to the physician, daily peak flowmonitoring, and a personal
medication plan. The control group did not receive the educa-
tional programme or CBT and were treated according to guide-
lines and followed up six times during the yearlong study.
Three studies provided classic CBT in a group format (Deshmukh
2008; Ross 2005; Yorke 2013).Deshmukh 2008 tested a five-week
group cognitive behavioural intervention (four sessions) against
an asthma-monitoring control group, although the content of the
sessions was unclear. The CBT model used in Ross 2005 was
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derived from Barlow panic control treatment and Beck cognitive
treatment for panic disorder, and consisted of 12 90-minute group
sessions over eight weeks, compared with a waitlist control group
who were offered the intervention after the study. Yorke 2013
administered eight 90-minute group sessions of CBT based on a
manual (Antoni 2003), and the control group received usual care.
One study integrated participants in the intervention group into
mindfulness-based stress reduction (MBSR) group sessions and of-
fered control group participants a “healthy living course” with the
same amount of contact (eight-weekly 2.5-hour sessions plus a 6-
hour session onweek six) (Pbert 2012).MBSR includedbody scan,
sitting meditation with a focus on breathing awareness, thoughts,
and feelings; gentle stretching exercise, emphasising integration
into everyday life to support coping with symptoms and stress;
and CD-based mindfulness exercises for home practice.
We investigated intervention format (individual or group sessions)
and themodel ofCBTwith planned subgroup analyses. Additional
variation among studies in session number and length, and the
type of control group makes some of the results more difficult to
interpret; we have commented on this in the Discussion.
Outcomes
The studies generally measured similar types of outcomes, but the
scales and definitions used varied considerably, particularly with
regard to psychological symptoms.
In terms of asthma outcomes, all studies except Sommaruga 1995
measured quality of life, mostly with the Asthma Quality of Life
Questionnaire (AQLQ), used in Deshmukh 2008, Grover 2002,
Grover 2007, Pbert 2012, Put 2003, Ross 2005, and Yorke 2013
(Juniper 1999), but also with the Asthma Bother Profile, used
in Grover 2007 and Parry 2012 (Hyland 1995), or general mea-
sures such as the EQ-5D, used in Parry 2012 and Yorke 2013.
Deshmukh 2008 data were calculated from individual participant
data on a poster graph provided by the study authors. Measures
of asthma symptoms and control included the Asthma Symptom
Checklist (ASC), used in Grover 2002, Grover 2007, Parry 2012,
Put 2003, and Sommaruga 1995 (Brooks 1989), often including
the panic-fear subscale as a measure of asthma-related anxiety; the
Asthma Control Questionnaire (ACQ) and Dyspnoea-12, both
used in Yorke 2013 (Juniper 1999a; Yorke 2011); NIH/NHLBI
asthma control categorisations, used in Pbert 2012 (NIH/NHLBI
2007); and non-validated measures including asthma diary data
such as rescue medication use, peak flow, and symptom-free days
(Grover 2002; Grover 2007; Pbert 2012; Ross 2005; Yorke 2013).
Five studies measured peak expiratory flow (Grover 2002; Grover
2007; Pbert 2012; Put 2003; Ross 2005). Other outcomes mea-
sured emotions and attitudes relating to asthma such as asthma-
related emotional functioning (Deshmukh 2008), health locus of
control (Parry 2012; Sommaruga 1995), Knowledge, Attitude,
and Self-Efficacy Asthma Questionnaire, used in Put 2003, and
the Respiratory IllnessOpinion Survey (cited in Sommaruga 1995
through personal communication) (Wigal 1993).
In terms of psychological outcomes, anxiety was measured by the
Hospital Anxiety and Depression Scale used in Deshmukh 2008,
Grover 2007, Parry 2012, andYorke 2013 (Zigmond 1983), State-
Trait Anxiety Inventory, used in Grover 2002 and Sommaruga
1995 (Spielberger 1983), and panic-specific outcomes were mea-
sured in Ross 2005 due to the comorbid population. Depres-
sion was measured by the Beck Depression Inventory, used in
Grover 2002 and Ross 2005 (Beck 1961), Negative Emotionality
Scale, used in Put 2003 (Tellegen 1988), and Depression Ques-
tionnaire, used in Sommaruga 1995 (Sanavio 1986). Other psy-
chological outcomes included the Perceived Stress Scale, used in
Pbert 2012 (Cohen 1983), a semi-structured interview schedule,
used in Grover 2007, and the Anxiety Sensitivity Index, used in
Ross 2005 (Peterson 1992). Put 2003 also measured adherence,
and Yorke 2013 was the only study to measure acceptability of the
intervention.
Excluded studies
After viewing the full-text publications we excluded 42 studies.
The most common reason for exclusion was that the intervention
did not meet the inclusion criteria of CBT.We excluded nine stud-
ies because they were not randomised controlled trials, five studies
because they recruited child populations, and one study because
the population included people with asthma or COPD. It was dif-
ficult to ascertain the nature of interventions from abstracts alone,
and even from the full-texts, especially when the intervention in-
cluded cognitive and behavioural elements but was not described
as CBT. This led to several discussions regarding inclusion and
the application of the eligibility criteria, and a large number of
excluded studies to properly document this process.
In addition to the excluded studies, we listed three studies as
ongoing (ACTRN12614000915651; IRCT2015061622770N1;
NCT01583296). ACTRN12614000915651 is an Australian trial
of telephone-delivered CBT and will include participants with
asthma and other lung diseases undergoing pulmonary rehabil-
itation (COPD, idiopathic pulmonary fibrosis, bronchiectasis),
so it will only be eligible for inclusion in a future update if dis-
aggregated data are made available. The authors of this study
aim to recruit 100 participants, but the study, which was due to
start in September 2014, is listed as “not yet started recruiting”.
IRCT2015061622770N1 is a study of mindfulness-based cogni-
tive therapy for women with asthma, evaluating its effect on anx-
iety, depression, and somatic symptoms. The study is being con-
ducted in Iran, was registered in December 2015, and aims to re-
cruit 30 participants. NCT01583296 has the acronym LUCHAR
and is listed as completed, but currently has no listed publications
or data posted on ClinicalTrials.gov. It is a study of CBT with
heart rate variability feedback versus Music Relaxation Therapy
(MRT), and so may not meet the inclusion criteria for this review
since it has an active comparison. The study is being conducted
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in New York, USA and aimed to enrol 53 Latino participants.
Risk of bias in included studies
A summary of the risk of bias across studies is presented in Figure
3.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Weconsidered four studies to be at low risk of bias for both random
sequence generation and allocation concealment because they re-
ported adequate methods in the published reports (usual comput-
erised schedules implemented centrally) (Parry 2012; Pbert 2012;
Put 2003; Yorke 2013). We rated three studies as unclear for both
domains because they were described as randomised but with in-
sufficient details about methods to make a judgement about pos-
sible bias (Deshmukh 2008; Ross 2005; Sommaruga 1995). We
rated Grover 2002 as at unclear risk for random sequence genera-
tion for the same reason, and high risk for allocation concealment
because the report stated that participants were “sequentially al-
lotted to two groups”, which could have allowed for bias in imple-
mentation of the sequence. We rated Grover 2007 as at low risk
for sequence generation because a random number table was used,
but unclear for allocation concealment because no other details
were given.
Blinding
The behavioural nature of the interventions of interest in this
review could not be kept blind from participants and personnel.
As a result, we rated blinding of participants and personnel as high
risk of bias by default. However, when rating each outcome in
GRADE, we considered the differential effect performance bias
was likely to have had on subjective outcomes including self rated
questionnaires and objective outcomes such as exacerbations and
adverse events.
Regardless of the inability to blind participants and personnel, it
was possible to reduce bias for all outcomes by recruiting someone
not otherwise involved in the study to measure outcomes without
knowledge of allocation. We did not assume this was done and
rated studies high risk by default unless it was explicitly stated in
the study report or via personal communication.
Incomplete outcome data
We considered five studies to be at high risk of attrition bias:
Deshmukh 2008 included very low numbers in each group and
saw very high and unbalanced dropout; in Parry 2012, there was
very high andunbalanceddropout (60%and35% for intervention
and control), which is unlikely to have been fully accounted for
by the imputation for the intention-to-treat model; demographic
and outcome data in Ross 2005 were reported for the subset of
participants who completed, which was only 52% of those who
were randomised; we considered Sommaruga 1995 as at high risk
as no participants dropped out of the intervention group, whereas
20% of the control group dropped out during follow-up; in Yorke
2013, seven participants were removed after randomisation, which
may have biased the results, and there was a large amount of miss-
ing data from the asthma diaries due to poor adherence.
Attrition bias was unclear in Grover 2002 because only a con-
ference abstract was available, and we considered the remaining
studies as at low risk of attrition bias, either because there was no
dropout, because dropout was relatively low and balanced between
groups, or because imputation is likely to have appropriately ac-
counted for missing data.
Selective reporting
We rated four studies as at high risk of bias for selective reporting,
two of which were only available as conference abstracts, so very
little information was available regarding the conduct of the study
or the results (Deshmukh 2008;Grover 2002).We also rated Parry
2012 and Sommaruga 1995 as at high risk because some results
were only reported as “no significant difference” or at baseline and
not after treatment.
Risk of reporting bias was considered for each outcome separately
in the GRADE process, so a high-risk rating does not affect our
grading of other unrelated outcomes.
We rated the other five studies as at low risk of bias, either because
we were able to check the reported outcomes against a prospec-
tively registered protocol (Pbert 2012), or because outcomes listed
in the methods were fully reported in a way that allowed data to
be included in our analyses (Grover 2007; Put 2003; Ross 2005;
Yorke 2013).
Other potential sources of bias
We considered two studies to be at high risk of bias for another
reason: Sommaruga 1995 because the intervention group received
additional interventions, which may have confounded the result,
and Grover 2007 because there were baseline imbalances across
groups for the Asthma Bother Profile, ASC, and Hospital Anxiety
and Depression Scale. We rated the other seven studies as at low
risk of bias because no other biases were noted.
Effects of interventions
See: Summary of findings for the main comparison Cognitive
behavioural therapy versus usual care
Asthma-related quality of life
Six studies reported asthma-related quality of life on the AQLQ (
Deshmukh 2008; Grover 2007; Pbert 2012; Put 2003; Ross 2005;
Yorke 2013), showing a 0.55-point benefit of CBT over usual care
at the endof treatment (95%confidence interval (CI) 0.17 to 0.93;
Analysis 1.1). The primary endpoint measurements were taken
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between 5 and 16 weeks, depending on the length of treatment
across studies. As planned in our protocol, where available we used
change from baseline measurements. We considered the evidence
to be of low quality due to possible performance and attrition
bias, and variation between study results (I2 = 53%, P = 0.06). We
removed Deshmukh 2008 in a sensitivity analysis because there
was very high attrition in the control group (leaving only three
participants in that arm), and the datawere estimated froma poster
graph. The magnitude of the effect based on the remaining five
studieswas slightly smaller but still statistically significant in favour
of CBT (mean difference (MD) 0.48, 95% CI 0.07 to 0.89).
Follow-up data were available at 3 months for Deshmukh 2008,
6 and 12 months for Pbert 2012, and 6 months for Put 2003; all
showed a statistically significant effect of CBT over usual care on
the AQLQ (Analysis 1.2).
Deshmukh2008 also reported the number of participants showing
an important improvement on the AQLQ (i.e. meeting the scale’s
minimal clinically important difference (MCID) of 0.5 frombase-
line to end of treatment). The numbers were small, and only 3 of
the 8 participants in the control group could be followed up, but
the study reported that 6 out of 9 and 5 out of 9 in the CBT group
met the MCID at the end of treatment and 3-month follow-up,
and nobody in the control group.
Asthma exacerbations requiring at least a course of
oral steroids
Parry 2012, Pbert 2012, and Yorke 2013 reported outcomes that
could be interpreted as asthma exacerbations, but in very different
ways, so that they could not be meta-analysed.
Parry 2012 reported the number of participants in the six months
before treatment (but not in the period afterwards) that had been
admitted to hospital, which we have summarised in the unsched-
uled contacts outcome below. At post-treatment (10 weeks) and
at the 6- and 12 month follow-ups, Pbert 2012 reported the num-
ber of participants who had recently had a course of prednisolone
(within 30 days of measurement), but there were important dif-
ferences in recent predinisolone use at baseline (10 out of 41 CBT
and 2 out of 41 control) so it was difficult to interpret the results; 5,
5, and 7 participants out of 39 in the CBT group had recently had
a course of prednisolone at 10-weeks (post-treatment), 6-months
and 12-months, compared to 6, 2, and 7 participants in the con-
trol group, respectively. Two participants in the CBT group and
1 in the control group of Yorke 2013 recorded an emergency de-
partment or hospital visit for an exacerbation, but this was based
on a subset of 7 participants in each group with complete diary
card data.
We did not GRADE the quality of this evidence.
Asthma control
Three studies reported validated scales of asthma control, either
the ASC, in Grover 2007 and Put 2003, or the ACQ, in Yorke
2013. The pooled result showed an overall benefit of CBT over
usual care (standardised mean difference (SMD) -0.98, 95% CI -
1.76 to -0.20; participants = 95; Analysis 1.3), although there was
significant variation among the study results (I2 = 68%, P = 0.04).
We downgraded the evidence once for risk of performance and
attrition bias and once for inconsistency, and rated it low quality.
In addition to the validated scales pooled in the analysis, we noted
the following outcomes relating to asthma control.
• CBT did not reduce the need for rescue medication use per
week in Pbert 2012, ranging from 2.39 to 3.21 times across the
three time points in the CBT group (10 weeks, 6 months, and
12 months) and from 1.83 to 2.49 in the control group.
• In the same study, the number of participants meeting
NIH/NHLBI criteria for ’well-controlled’ was similar at the 10-
week endpoint (3/33 CBT and 5/37 control), but showed a
possible longer-term benefit of CBT at the 6-month (8/37 CBT
and 2/37 control) and 12-month follow-up (7/36 CBT and 3/38
control).
• In Ross 2005, the number of symptom-free days over two
weeks was similar in the CBT (6.69, standard deviation (SD)
5.72) and control groups (5.62, SD 4.98), based on 13 and 8
participants in the two groups after 8 weeks, respectively.
Unscheduled contacts with health services for asthma
Data about unscheduled contact was not generally reported, or not
in a way that could be meta-analysed. Parry 2012 reported data as
themean number of visits per participant over the six months after
treatment (Analysis 1.4), and did not find a difference between
CBT and control participants for general practitioner visits (MD -
0.28, 95% CI -1.36 to 0.80) or primary care visits including nurse
and out-of-hours contacts (MD -0.40, 95% CI -1.51 to 0.71).
We considered evidence for these outcomes to be of low quality
because the study was at high risk of performance and attrition
bias (risk of bias downgrade), and because the effects were based on
data from one study of 80 participants (imprecision downgrade).
Otherwise, as stated under the exacerbation outcome, 2 partici-
pants in the CBT group and 1 in the control group of Yorke 2013
recorded an emergency department or hospital visit for an exac-
erbation, but this was based on incomplete diary card data. Parry
2012 reported that 3 participants in the CBT group and 4 in the
control group were admitted to hospital in the six months before
treatment, but the numbers in each group were unclear, and the
equivalent poststudy data were not reported.
Validated scales of anxiety
We were unable to pool all anxiety data due to variation in the
scales and analyses used. We analysed studies in three unpooled
subgroups for anxiety measured as:
1. change from baseline (Parry 2012; Pbert 2012; Yorke 2013);
2. anxiety as endpoint scores (Parry 2012; Ross 2005;
Sommaruga 1995); and
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3. anxiety scores as a composite with depression (Grover 2007;
Yorke 2013).
These were presented as subgroups in one analysis (Analysis 1.5),
but the change scores were our primary analysis, as defined in our
protocol (Kew 2015). These could not be combined in a SMD
analysis, as the smaller change from baseline variances would have
given those studies more weight in the analysis.
Studies reporting change from baseline showed that CBT im-
proved anxiety scores compared with usual care (SMD -0.38, 95%
CI -0.73 to -0.03), but this was not backed up by the endpoint
scores analysis (SMD -0.25, 95% CI -1.02 to 0.51). There was
significant variation between study results in the endpoint score
(I2 = 76%, P = 0.01), but not in the change scores (I2 = 28%, P =
0.25). We primarily graded the change score analysis, but took the
endpoint analysis into consideration. We considered the evidence
to be of low quality due to possible performance and attrition bias
(risk of bias downgrade) and inconsistency between study results
and the two analyses (inconsistency downgrade).
Two studies reported change in the total Hospital Anxiety and
Depression Scale (HADS) anxiety and depression composite score
(Grover 2007; Yorke 2013). The studies showed very different
effects, which made the result difficult to interpret (SMD -0.62,
95% CI -1.84 to 0.59; I2 = 84%).
Validated scales of depression
Similarly to the anxiety outcomes, some studies reported depres-
sion scales as change from baseline (Parry 2012; Yorke 2013),
and others as endpoint scores (Put 2003; Ross 2005; Sommaruga
1995), which could not be pooled in a SMD analysis. The pooled
result from two studies reporting depression as change from base-
line, both using the HADS (SMD -0.33, 95% CI -0.70 to 0.05),
was similar to the pooled result of the three studies reporting end-
point scores (SMD -0.41, 95% CI -0.87 to 0.05); neither upper
confidence intervals ruled out no difference between CBT and
usual care. There was significant heterogeneity between the end-
point scores (I2 = 80%, P = 0.007), which may be due to each
study using different scales and time points (Negative Emotion-
ality Scale at 3 months in Put 2003, Beck Depression Inventory
at 8 weeks in Ross 2005, and Depression Questionnaire in Italian
at 52 weeks in Sommaruga 1995). As with the anxiety analyses,
we primarily graded the change score analysis, as this preference
was stated in our protocol, but we took the endpoint analysis into
consideration. We downgraded the evidence for publication and
attrition bias (risk of bias downgrade) and imprecision in the esti-
mate (imprecision downgrade).
Put 2003 also measured the Negative Emotionality Score at 6-
month follow-up, showing a similar but slightly smaller effect of
CBT than at the 3-month post-treatment measurement.
Medication adherence
Only one study used the Adherence Scale (Put 2003), on which
higher scores indicate poorer adherence. Themean score was lower
in the CBT group than in the usual care group, but the confi-
dence intervals for the effect did not exclude no difference between
groups (MD -1.40, 95% CI -2.94 to 0.14; participants = 23; stud-
ies = 1; I2 = 0%). Mean scores were similar in both groups at 6-
month follow-up. We downgraded the evidence twice for impre-
cision due to the very small number of participants in the analysis
and uncertainty in the effect, and rated it low quality.
Parry 2012 reported the number of prescriptions taken 6 months
before (1.53, SD 0.92 (CBT); 1.43, SD 1.40 (usual care)), during
(1.33, SD 1.40 (CBT); 1.32, SD 1.10 (usual care)), and 6 months
after treatment (1.27, SD1.30 (CBT); 1.00, SD1.30 (usual care)),
showing a slight reduction over time in both groups and no real
differences between them. It is unclear whether this outcome was a
measure of adherence to treatment (higher is better) or the number
of different prescriptions required for asthma control (lower is
better).
Subgroup analyses
We planned to conduct subgroup analyses on the three primary
outcomes: asthma-related quality of life, exacerbations requiring
at least a course of oral steroids, and asthma control. While we did
not specify a minimum number of studies needed to conduct the
subgroup analyses, only three studies contributed data to the sec-
ond and third primary outcomes, which we did not consider to be
sufficient for subgroup analyses. As such, we conducted subgroup
analyses on the asthma-related quality of life outcome only. The
observational nature of subgroup analyses, along with the small
number of studies and variation between their designs, popula-
tions, and other intervention characteristics, limited our confi-
dence in the subgroup analyses.
Individual versus group CBT
Of the six studies reporting the AQLQ, two used an individual
CBT format (Grover 2007; Put 2003), and four used a group
format (Deshmukh 2008; Pbert 2012; Ross 2005; Yorke 2013).
There was some heterogeneity within both subgroups, and the test
for subgroup differences was not statistically significant (I2 = 11%,
P = 0.29).
Mean age
We were unable to make the comparison of adolescents (younger
than 18 years) and adults because all of the included studies re-
cruited adult populations.
Baseline psychological symptoms
The results of the three studies recruiting populations with evident
psychological symptoms at baseline varied widely among studies
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(I2 = 65%, P = 0.06) (Deshmukh 2008; Ross 2005; Yorke 2013),
which meant that the subgroup effect had extremely wide confi-
dence intervals. Studies that did not recruit participants on the ba-
sis of psychological symptoms also varied significantly within the
subgroup (I2 = 60%, P = 0.08). The test for differences between
the two subgroups was not significant (I2 = 0%).
Types of CBT
As with the other subgroup analyses, variation within the sub-
groups outweighed differences between them. There was much
heterogeneity (I2 = 49%, P = 0.10) among the five studies using
a classic CBT model (Deshmukh 2008; Grover 2007; Put 2003;
Ross 2005; Yorke 2013), and the test for subgroup differences be-
tween these studies and the one study using a mindfulness model,
Pbert 2012, was not significant (I2 = 38%, P = 0.20).
Sensitivity analyses
Studies at high risk of bias for blinding of outcome assessors
We rated none of the studies as at high risk for detection bias. We
rated two studies as at low risk (Pbert 2012; Put 2003), and we
did not know whether outcome assessors were blind in the rest.
For the first primary outcome, AQLQ, limiting the analysis to the
two studies rated as at low risk did not have a large impact on
the point estimate (MD 0.61), but the confidence intervals were
much wider (95% CI -0.11 to 1.32), and there was inconsistency
between the two results (I2 = 80%, P = 0.03).
Only one of the low-risk studies, Put 2003, appeared in the second
primary outcome analysis for asthma control, and the effect for
this study alone (SMD -0.90, 95% CI -1.77 to -0.04) was similar
to the pooled result for all three in the analysis (SMD -0.98, 95%
CI -1.76 to -0.20).
We were unable to perform a meta-analysis for the third primary
outcome, exacerbations requiring oral steroids, so it did not make
sense to do a sensitivity analysis.
Unpublished data
We calculated Deshmukh 2008 AQLQ data from a graph on a
poster provided by the study authors. These data were not avail-
able in the associated abstract, and the study has not been fully
published. In addition, calculating mean change scores from the
bar graph of baseline, endpoint, and follow-up scores of each par-
ticipant involved somemeasurement error and imprecision.When
we removed these data from a sensitivity analysis from the primary
endpoint, the magnitude of the effect was slightly smaller, but still
statistically significant in favour of CBT (MD 0.48, 95% CI 0.07
to 0.89).
No unpublished data contributed to the other two primary out-
comes, asthma control and exacerbations requiring oral steroids.
D I S C U S S I O N
Summary of main results
We found nine randomised trials including 407 adults with
asthma. Study size ranged from 10 to 94 (median 40), and mean
age ranged from 39 to 53. Study populations generally had per-
sistent asthma, but severity and diagnostic measures varied. Three
studies recruited participants with a psychological symptomatol-
ogy, although with very different criteria.
Most studies used a classic model of CBT, given either individu-
ally, in Deshmukh 2008, Grover 2002, Grover 2007, Parry 2012,
and Put 2003, or in a group (Ross 2005; Yorke 2013), and one
study tested a group mindfulness intervention (Pbert 2012). In-
terventions ranged from 4 to 15 sessions, and primary measure-
ments were taken at a mean of 3months (range 1.2 to 12months),
and there was also variation in the control groups. Studies gen-
erally measured similar outcomes, but the scales and definitions
used varied considerably, particularly with regard to psychological
symptoms. The inability to blind participants and investigators to
group allocation introduced a serious potential for bias, and high
dropout was also an issue in some studies. Evidence quality was
low, often affected by these risks of bias in combination with either
imprecision or inconsistency between study results.
Participants given CBT had improved scores on the AQLQ (MD
0.55, 95% CI 0.17 to 0.93; participants = 214; studies = 6; I2 =
53%) and on measures of asthma control (SMD -0.98, 95% CI -
1.76 to -0.20; participants = 95; studies = 3; I2 = 68%) compared
to participants getting usual care. The AQLQ effect appeared to
be sustained up to a year after treatment, but all of the evidence
must be interpreted with caution due to the low quality of the
evidence. Asthma exacerbations requiring at least a course of oral
steroids were not consistently reported, so we could not perform
a meta-analysis.
Datawere generally sparser for the secondary outcomes.One study
of 80 participants that could be analysed for unscheduled contacts
did not show a difference between CBT and usual care for general
practitioner visits (MD -0.28, 95% CI -1.36 to 0.80) or primary
care visits including nurse and out-of-hours contacts (MD -0.40,
95% CI -1.51 to 0.71) (Parry 2012). Anxiety scores were difficult
to pool but showed a benefit of CBT compared with usual care
(SMD -0.38, 95% CI -0.73 to -0.03), although this depended
on the analysis used. The confidence intervals for the effect on
depression scales included no difference between CBT and usual
care when measured as change from baseline (SMD -0.33, 95%
CI -0.70 to 0.05) or endpoint scores (SMD -0.41, 95% CI -0.87
to 0.05), and the same was true for medication adherence (MD -
1.40, 95% CI -2.94 to 0.14; participants = 23; studies = 1; I2 =
0%).
Subgroup analyses conducted on the AQLQ outcome did not sug-
gest a clear difference between individual and group CBT, baseline
psychological status, or CBT model. The small number of studies
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and the variation between their designs, populations, and other
intervention characteristics limited the conclusions that could be
drawn about these possibly moderating factors.
Overall completeness and applicability of
evidence
Several factors warrant consideration when interpreting the com-
pleteness and applicability of the present findings. The search strat-
egy was designed to identify interventions that included CBT as
the main active component. The nine studies included in this re-
viewmostly used a classic CBTmodel, although the delivery of the
intervention varied (including individual and group therapy), and
the number and duration of CBT sessions was mixed. There was
patchy detail across studies about the actual content of CBT, who
had delivered the intervention, intervention fidelity, and possible
contamination during the course of the study, making replication
and application of the results difficult.
We specified ’usual care’ as the comparator of interest to keep the
comparison as pure as possible, but control groups varied more
than anticipated, which makes the results harder to interpret. In
practice, the control groups varied, with descriptions including
no treatment (Parry 2012), waiting list (Pbert 2012; Ross 2005),
standard pharmacological care (Grover 2002), usual care (Yorke
2013), and asthma monitoring (Deshmukh 2008). Participants
in the control group of Grover 2007 received a self monitoring
programme, which the intervention group also received on top
of CBT; given that the effects of the self monitoring programme
would theoretically cancel out, this study fits our inclusion crite-
ria. We were satisfied that the control groups across these seven
studies received something akin to ’usual care’, which would of
course differ across study contexts and likely be more intensive
than real-life care, due to study assessments, etc., which is the case
in any meta-analysis of trials. The control groups in Pbert 2012
and Sommaruga 1995 were more complicated and may have in-
troduced clinical heterogeneity into the analyses to which they
contributed, particularly as Pbert 2012 used a third-wave group
mindfulness intervention that differed from the classic models
used in the other studies. Pbert 2012 gave a “Healthy Living
Course”, which matched the contact of the intervention group to
isolate the specific effects of CBT, and aspects of the CBT group in
Sommaruga 1995 (peak flow measurements, access to physician,
and asthma education) were not well controlled for in the con-
trol group, who were followed up more regularly than could be
considered ’usual care’ (six times over the course of the year). We
considered the study comparisons to broadly match the eligibility
criteria set out in our protocol, but were nonetheless cautious in
our conclusions due to this variation.
Our seven predetermined outcomes were reported in at least one
study. Our primary outcomes of asthma-related quality of life and
asthma exacerbations are relevant outcomes in asthma, however
not all studies included these and often used different mechanisms
to assess these outcomes. This made pooling of the data difficult,
andwe could performmeta-analysis on six studies using theAQLQ
(Deshmukh 2008; Grover 2007; Pbert 2012; Put 2003; Ross
2005; Yorke 2013). We set five secondary outcomes, which were
measured in a variety of ways across different studies. Anxiety was
assessed in six studies (Grover 2007; Parry 2012; Pbert 2012; Ross
2005; Sommaruga 1995; Yorke 2013), and depressionwas assessed
in five studies (Parry 2012; Put 2003; Ross 2005; Sommaruga
1995; Yorke 2013), however variation in the scales used prevented
meta-analysis for these outcomes. The remaining three outcomes
were reported less frequently, limiting our ability to conduct any
meaningful meta-analyses.
All 407 participants were reported to have a confirmed diagnosis
of asthma, although the mechanism of diagnosis was not always
clearly stated. Psychological symptomatology is especially relevant
in severe asthma, and only one study specifically focused on this
group (Yorke 2013). Three studies assessed psychological symp-
toms as inclusion criteria (Deshmukh 2008; Ross 2005; Yorke
2013), although each study applied a different method of assess-
ment. Differences in the psychological symptomatology of the
study populations raise an important question of who with asthma
might best benefit from CBT, but this could not be teased out
in this review due to the different inclusion criteria used and the
number of studies. Additionally, all of the studies recruited adult
populations, so we were unable to draw any conclusions relating
to the efficacy of CBT in adolescent populations.
It is therefore not possible to draw any firm conclusions as to the
efficacy of CBT in the management of asthma.
Quality of the evidence
We assessed all of the evidence presented in this review as of low
quality, meaning “our confidence in the effect estimate is limited”
and “the true effectmay be substantially different from the estimate
of the effect” (GRADEpro GDT 2016). We did not pool any data
for one of the primary outcomes, asthma exacerbations requiring
at least a course of oral steroids, andwe did not attempt toGRADE
the quality of the narrative data.
We downgraded evidence for four outcomes for risk of bias
(asthma-related quality of life, asthma control, and validated scales
of anxiety and depression), primarily because the subjective nature
of rating scales may have allowed for bias due to the inability to
blind participants and personnel to group assignment. In addition,
we considered high or unbalanced dropout to be an issue in five
studies, which may have introduced further bias in the outcomes
to which they contributed (Deshmukh 2008; Parry 2012; Ross
2005; Sommaruga 1995; Yorke 2013). We did not downgrade
the evidence for the outcome ’unscheduled contacts with health
services for asthma’ because it was unclear whether knowledge of
treatment allocation would have affected this outcome as it did the
subjective rating scales. There was a risk of attrition bias for this
outcome, so these issues are still worth considering, even though
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we did not consider them sufficient to warrant downgrading the
evidence.
There was important variation between study results for three out-
comes (asthma-related quality of life, asthma control, and vali-
dated scales of anxiety), which led to downgrades. For quality of
life and asthma control, the overall heterogeneity between study
results was 53% and 58%, respectively, which was deemed sta-
tistically significant at the 0.10 level recommended for the test
(Higgins 2011). For the anxiety scales, the variability in scales used
meant we had to combine results using standardised mean dif-
ference, which prevented us pooling change scores with endpoint
measurements. Thismade it difficult to assess overall heterogeneity
across the outcome, but we chose to downgrade because there was
important variation between the endpoint scores (I2 = 76%, P =
0.01) and inconsistency between the pooled effects depending on
whether studies reported changes or endpoint measurements. We
faced a similar dilemma for the validated scales of depression out-
come but chose not to downgrade in that instance because while
there was important variation between studies reporting endpoint
scores, studies reporting change scores were consistent with each
other, and the pooled effects for changes and endpoints were in
agreement with each other.
Our confidence in the evidence for three of the outcomes was re-
duced by imprecision in the estimates (unscheduled contacts, val-
idated scales of depression, and medication adherence). For two
of these outcomes, unscheduled contacts and medication adher-
ence, we could analyse only one study (Parry 2012 and Put 2003,
respectively), and the small number of participants in the analyses
led us to downgrade each of these outcomes twice for imprecision.
It was not possible in either case to say with any certainty that
CBT is likely to have any benefit, or indeed cause harm, compared
with usual care. The imprecision in the depression analysis was less
severe, but it still prevented us from ruling out the possibility that
CBT is no better than usual care, so we downgraded the outcome
once.
We did not downgrade any outcomes for indirectness of the ev-
idence to the question we set out to answer in the systematic re-
view. While some studies looked at more specific populations than
others (e.g. Yorke 2013 recruited only people with severe asthma),
none of the studies included participants or tested interventions
that did not meet the inclusion criteria for this review. The inter-
vention group in Sommaruga 1995 received additional interven-
tions, which may have confounded the results in that study, but
we did not deem this sufficient to downgrade the two outcomes to
which it contributed (validated scales of anxiety and depression).
We did not downgrade any of the outcomes for publication bias
because we did not strongly suspect in any case that unpublished
datawould have changed the effects we observed or our confidence
in them.
Potential biases in the review process
As with any systematic review, there is an element of subjectivity
when deciding what should and should not be pooled in a meta-
analysis, which was particularly relevant in this review due to the
range of scales and analysis methods used across studies. We at-
tempted to reduce any bias that might be associated with these
decisions by following the published protocol (Kew 2015), and
being transparent in describing narratively anything that we de-
cided not to pool.
The author team expanded after the protocol was written, which
allowed us to extract study characteristics in duplicate to reduce
the potential for error.We also found a large number of potentially
eligible studies that needed to be considered in more detail, and
this led to a more lengthy duplicate process of consideration. As
described in the protocol, we have logged all references that were
considered in detail during this process as excluded studies with
explanations of our rationale for not including them in the review.
Otherwise, we did not make any changes to the protocol except
where it was not possible to follow the protocol due to the number
of studies, and we have recorded these in the Differences between
protocol and review section.
Agreements and disagreements with other
studies or reviews
A previous Cochrane review investigated the effects of any psycho-
logical intervention for people with asthma (Yorke 2006). This re-
view assessed 15 studies of 687 participants across a range of inter-
ventions (CBT, cognitive therapy, behavioural therapy, relaxation,
biofeedback, and counselling), and was limited in conclusions that
could be drawn from it by variation in the interventions studied,
small studies, and incomplete reporting. Of the 15 included stud-
ies, the majority assessed a form of relaxation technique includ-
ing hypnosis, functional or progressive relaxation, mental imagery,
and autogenic training. An earlier non-Cochrane review focus-
ing on relaxation therapies found 15 randomised controlled trials
(Huntley 2002), but neither review found evidence for efficacy of
such techniques in asthma. Refining the scope of the Yorke 2006
review to shift the focus to CBT, we found nine studies of 407 par-
ticipants, only three of which were included in Yorke 2006. The
refined scope and the number of CBT trials conducted since 2006
have allowed this current review to make more focused conclu-
sions, finding evidence that people with asthma given CBT may
have improved scores on the AQLQ and improved asthma control
and anxiety levels. However, both reviews rely on low-quality evi-
dence due mainly to possible internal biases and lack of precision,
meaning further studies may still change the conclusions or our
confidence in them.
We are not aware of other systematic reviews assessing the effect
of CBT on psychological and asthma outcomes for people with
asthma, but numerous Cochrane and non-Cochrane systematic
reviews have found benefits of CBT over no treatment for other
physical conditions (e.g. Bernardy 2013; Martinez-Devesa 2010;
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Monticone 2015; Price 2008). These reviews often have similar
reservations to ours regarding the quality of evidence, often due to
small trials. There is oftendisparity betweenbenefits onpsycholog-
ical and condition-specific outcomes, and asthma may be unique
in this regard due to the overlap and interaction between breath-
ing difficulties, hyperventilation, and panic. Other CBT reviews
including head-to-head comparisons generally fail to show superi-
ority of CBT over other psychological treatments (e.g. Monticone
2015), which we did not address in our review, and this may be a
possible area for future investigation in asthma.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For people with persistent asthma, CBT may improve quality of
life, asthma control, and anxiety levels compared with usual care.
Risks of bias, imprecision of effects, and inconsistency between
results reduced our confidence in the results to low, and evidence
was lacking regarding the effect of CBT on asthma exacerbations,
unscheduled contacts with health services for asthma, depression,
and medication adherence. There was much variation between
studies in howCBTwas delivered andwhat constituted usual care,
meaning the most optimal method of CBT delivery, format, and
target population requires further investigation. There is currently
no evidence for the use of CBT for adolescents with asthma.
Implications for research
Pooled effects suggest CBT may have modest benefits for people
with asthma, but it remains unclear who is most likely to benefit,
from what sort of programme, and whether CBT is superior to
other psychological interventions. The evidence could be better
applied by stratifying results by age, asthma severity, or scores
on psychological scales within studies, and/or with head-to-head
comparisons of different CBT formats and programmes to explore
resource implications. The current evidence offers little insight
into possible harms ofCBT,which could be reported inmore detail
in studies of this nature, and evidence for younger populations is
lacking.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Deshmukh 2008
Methods Parallel RCT conducted in Australia. 5 weeks end of treatment with a 3-month follow-
up
Participants 18 participants were randomised to CBT (10) or the control group (8)
Baseline characteristics: Mean age was 46 (SD 12) in the CBT group and 53 (SD 13)
in the control group. Percentage male was 40% in the CBT group and 12.5% in the
control group
Baseline psychological status: Inclusion criteria required participants to have anxiety
but did not specify criteria
Inclusion criteria: Participants identified with comorbid anxiety and asthma
Exclusion criteria: Not reported
Interventions Intervention: 4-session CBT intervention
Delivered by: Qualifications not described
Control: Asthma monitoring control group
Amount of contact: Unclear duration of each session in the intervention group. The
control group were given no additional contact
Outcomes Asthma-related emotional functioning, AQLQ,HADS anxiety and depression subscales
Notes Funding: Not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no details
(conference abstract only)
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The interventions could not be kept blind
from participants and personnel. By de-
fault, this is high risk of bias for subjec-
tive outcomes including self rated question-
naires, but probably would not introduce
bias for more objective outcomes such as
exacerbations and adverse events
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors could have been blind,
but there was no description in the study
of whether or how this was done
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Deshmukh 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 5 out of 8 people in the control group
dropped out and were not included in the
analysis (62.5%), compared with 1 out of
10 in the intervention group (10%)
Selective reporting (reporting bias) High risk Conference abstract only, no full publica-
tion. Emotional functioning and AQLQ
were only reported dichotomously, and
continuous scores were not available in
the abstract. AQLQ scores were displayed
graphically on the poster provided by the
authors, which could be included in meta-
analysis, but not the HADS results
Other bias Low risk None noted.
Grover 2002
Methods Parallel RCT conducted in 1 outpatient department in Bangalore, India. Duration of
intervention was unclear as study was only available as a conference abstract
Participants 10 participants were randomised to CBT (5) or the control group (5)
No baseline characteristics reported as currently only available as a conference abstract
Baseline psychological status: Not reported
Inclusion criteria: No information
Exclusion criteria: No information
Interventions Intervention: 15 individual sessions of CBT consisting of asthma education, Jacobson
progressive muscle relaxation (JPMR), behavioural techniques, cognitive restructuring,
cognitive coping skills, and behavioural counselling to significant others
Delivered by: Qualifications not described
Control: Standard pharmacotherapy alone
Amount of contact: Unclear duration of each session in the intervention group or over
how many weeks it was delivered. The control group were given no additional contact
Outcomes ASC, asthma diary, STAI, BDI, AQLQ, and PEFR
Notes Funding: Not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “experimental design with pre- and post-
therapy assessments”
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Allocation concealment (selection bias) High risk “sequentially allotted to two groups”, could
have allowed for bias in allocation to groups
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The interventions could not be kept blind
from participants and personnel. By de-
fault, this is high risk of bias for subjec-
tive outcomes including self rated question-
naires, but probably would not introduce
bias for more objective outcomes such as
exacerbations and adverse events
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors could have been blind,
but there was no description in the study
of whether or how this was done
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No description of any dropout - minimal
information in the conference abstract
Selective reporting (reporting bias) High risk None of the outcomes were reported in suf-
ficient detail to include in the meta-analy-
sis
Other bias Low risk None noted.
Grover 2007
Methods Parallel RCT conducted in 1 outpatient department in Bangalore, India. The inter-
vention lasted between 6 and 8 weeks, and data were collected over 23 months from
November 1999 to October 2001
Participants 40 participants were randomised to CBT plus self management (20) or self management
alone (20)
Baseline characteristics: Minimal reported - no mean age, percent male, % smokers,
or baseline lung function
Baseline psychological status: Participants with a clinical history of psychiatric illness
and those on anti-anxiety and antidepressant medication were excluded
Inclusion criteria: Individuals with a diagnosis of asthma (according to American Tho-
racic Society criteria 1987), age 18 to 45 years, duration of illness at least 2 years, and
working knowledge of Hindi/English
Exclusion criteria: People with other medical conditions involving breathing difficul-
ties; presence of other medical conditions such as coronary heart disease, diabetes, or
hypertension; clinical history of psychiatric illness; history of exposure to structured psy-
chological intervention
Interventions Intervention: Asthma self management (as below) plus cognitive restructuring, skills
training (problem solving, social), imaginary rehearsal, role-plays, weekly activity sched-
ule, and homework assignments
Delivered by: “therapist” - qualifications not described
Control: ASMP based on National Institutes of Health criteria, modified to suit the
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population. Included asthma education, training in self management behaviour, guided
self management plan, self management with an asthma diary, discussion on negative
emotions and asthma, breathing exercises, and behavioural counselling to significant
others
Amount of contact: 15 one-hour sessions in the intervention group and 10 one-hour
sessions in the control group. Both were given over 6 to 8 weeks
Outcomes SSIS, ASC, asthma diary, ABP, HADS, AQLQ, and PEFR
Notes Funding: Not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “After informed consent and baseline as-
sessment, patients were randomly allotted,
using random number table”
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The interventions could not be kept blind
from participants and personnel. By de-
fault, this is high risk of bias for subjec-
tive outcomes including self rated question-
naires, but probably would not introduce
bias for more objective outcomes such as
exacerbations and adverse events
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors could have been blind,
but there was no description in the study
of whether or how this was done
Incomplete outcome data (attrition bias)
All outcomes
Low risk No mention of any dropout.
Selective reporting (reporting bias) Low risk PEFR only available graphically, but the re-
view did not consider lung function, and
the SSIS was not reported, however again
we did not consider this an important out-
come for the review
Other bias High risk “groups were comparable on socio-demo-
graphic and clinical variables such as age,
sex, marital status, education, religion, oc-
cupation, family history of asthma, work
loss, hospital admission, duration of illness
and emergency room visits. Groups were
not comparable on baseline assessment on
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ABP-B (P < 0.01), ASC (P < 0.05) and
HADS (P < 0.01).”
Parry 2012
Methods Parallel RCT conducted at 16 medical centres in the UK. Investigators approached
family doctors, outpatient and inpatient centres in Sheffield to identify participants. The
intervention lasted between 6 and 13 weeks
Participants 94 participants were randomised to CBT (50) or the control group (44)
Baseline characteristics: Mean age was 44 in the CBT group and 43 in the control
group. Percentage male was 32 in the CBT group and 39 in the control group. FEV not
given but did state that 17/50 in the CBT group and 16/44 in the control group had
severe asthma (> 25% reduction of FEV1). For both groups, baseline data were reported
separately for those who completed and those who withdrew or were lost to follow-up.
We have merged the 2 groups to show the characteristics of all randomised participants
in each group
Baseline psychological status: “highly anxious” as per HADS anxiety scale or ASC
panic fear score cutoffs
Inclusion criteria: Aged 18 to 65, clinical diagnosis of asthma, above threshold on
clinical criteria of anxiety using published cutoff points on the HADS Anxiety and ASC
panic fear subscale (ASC-PF). Score of 8 or more on the HADS anxiety or 28 or more
on the ASC-PF were eligible. Asthma diagnosis was based on a clinical picture of airflow
obstruction with diurnal variation in symptomatology and clinical evidence of airways
hyper-irritability
Exclusion criteria: HADS < 4, age under 18 or over 65, unable to read and complete
questionnaire in English, severe psychiatric illness with history of hospital admission,
diagnosed heart failure or angina, significant comorbid lung disease
Interventions Intervention: CBT with therapist based on asthma-specific fears, promoting awareness
of anxiety-provoking cognitions and beliefs, controlled exposure and tolerance to reduce
dysfunctional somatic preoccupation and safety-seeking, breathing techniques, postural
adjustments and relaxation for hyperventilation, identifying triggers to panic fear, and
problem-solving skills. The intervention group were followed up at 6 months
Delivered by: 4 therapists: 3 clinical psychologists and 1 cognitive behavioural therapist
(none specialised in asthma)
Control: Treatment delayed until the intervention post-treatment measurement. The
control group ’post-treatment’ assessment took place 3 months after baseline, and the
follow-up after 9 months
Amount of contact: The intervention group had a 1.5-hour introductory session fol-
lowed by 4 to 6 sessions either weekly or fortnightly; treatment lasted between 6 and 13
weeks. The control group received no additional contact during the intervention phase
Outcomes Primary clinical outcome measure: ASC-PF at 6 months after end of treatment (clin-
ically significant fear = 28)
Secondary outcomes: EQ-5D, HADS, ABP, AMHLC, all self-completed at baseline,
end of treatment, and 6months after end of treatment (baseline, 3months, and 9months
for control participants). Mean time to collection of the second endpoint data was 53
weeks for the treatment group (range 35 to 74 weeks) and 51 weeks for the control group
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(range 37 to 74 weeks)
The ANCOVA analyses were adjusted for baseline ASC score, age, group, gender, and
smoking
Notes Funding: Department of Health for England and Wales Asthma Management Pro-
gramme
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “an independent statistician who was a
member of data monitoring group gener-
ated a blocked and stratified by asthma
severity and socioeconomic status ran-
domisation schedule by computer”
Allocation concealment (selection bias) Low risk “The research associate assigned the partic-
ipants to treatment groups in strict sequen-
tial order according to the schedule and
informed them of the allocation by tele-
phone”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The interventions could not be kept blind
from participants and personnel. By de-
fault, this is high risk of bias for subjec-
tive outcomes including self rated question-
naires, but probably would not introduce
bias for more objective outcomes such as
exacerbations and adverse events
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors could have been blind,
but there was no description in the study
of whether or how this was done
Incomplete outcome data (attrition bias)
All outcomes
High risk “The main analyses were by intention to
treat to reduce bias due to differential at-
trition from the intervention and control
groups. For participants withdrawn on the
basis of clinical assessment (Fig. 1) data at
endpoint 1 and 2 were imputed as zero
change as it was assumed that these par-
ticipants would not have benefited from
CBT. For all other missing data imputation
was last observation carried forward.” “All
randomised patients were followed up and
included in the analysis where data were
available, irrespective of whether they com-
pleted treatment. More participants com-
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pleted outcome measures at the second
endpoint than at the first endpoint. The
numbers analysed for each group were as
follows: first endpoint: 20 CBT, 29 con-
trol; second endpoint: 28 CBT, 31 con-
trol.” Data for only 20 of the 50 interven-
tion group participants (40%) and 29 of
the 44 control group participants (65%)
were available at the end-of-treatment time
point, representing very high and unbal-
anced dropout, which may not have been
adequately controlled for by the imputa-
tion
Selective reporting (reporting bias) High risk Results for the anxiety subscale of the
HADS were only reported as “no signif-
icant difference”. Number of participants
admitted to hospital was only given for the
period before treatment
Other bias Low risk None noted.
Pbert 2012
Methods Parallel RCT conducted at a university hospital outpatient primary care and pulmonary
care clinic in Massachusetts, USA. The intervention lasted for 8 weeks
Participants 83 participants were randomised to MBSR (42) or the “Healthy Living Course” control
group (41)
Baseline characteristics:Mean agewas 52 in themindfulness group and54 in the control
group. Percentagemale was 36% in themindfulness group and 39% in the control group.
Participants in the mindfulness group had a mean percentage predicted FEV1 of 91.7%
(SD 16.6), and those in the control group had a mean of 94.6 (SD 18.9). 80.0% in the
control group and 83.8% in the mindfulness group were on inhaled corticosteroid or
oral prednisone. Many other baseline characteristics were also reported including race,
education, marital status, asthma control category, asthma severity category, other lung
function metrics, rescue inhaler and othermedication use, AQLQ, PSS, school and work
absence
Baseline psychological status: People with a psychiatric hospital admission in the pre-
vious 2 years or who had taken psychotropic medications in the past year were excluded
Inclusion criteria: Physician-documented asthma with an objective indicator of
bronchial hyper-responsiveness (positive methacholine challenge test, at least 12% im-
provement in FEV1 or FVC in response to bronchodilator, or 20% variability in diurnal
PEF variation), or at least 12% improvement in FEV1 in response to inhaled bron-
chodilator on spirometry at study entry (2007 NIH/NHLBI criteria for mild, moder-
ate, or severe persistent asthma). Able to read and understand English, able to complete
informed consent process and study data collection procedures
Exclusion criteria: Intermittent asthma (symptoms less than once/week, brief exacerba-
tions, nocturnal symptoms less than or equal to twice amonth, and normal lung function
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between episodes); smoked in the past year; other lung diseases; current treatment for
symptomatic cardiovascular disease; history of a positive tuberculosis test; participated
in MBSR and/or practicing meditation regularly. Additional from NCT site: cancer ex-
cept non-melanoma skin cancer, on psychotropic medications in the prior 12 months,
psychiatric hospitalisation in the past 2 years
Interventions Intervention: Participants were integrated into regularly scheduledMBSR classes, which
had approximately 2 study and 28non-study participants.Mindfulness training included
body scan, sitting meditation focusing on awareness of breathing, thoughts and feelings,
and gentle stretching exercises to develop awareness during movement, emphasising inte-
gration into everyday life to support coping with symptoms and stress. 2 CDs containing
guided mindfulness exercises were provided to be practiced for 30 minutes, 6 days/week
Delivered by: Qualifications not described
Control: HLC was offered to community members in addition to study participants
and consisted of approximately 7 study and 18 non-study participants. HLC matched
the intervention for time, instructor attention, and format. Classes consisted of lectures
and discussion of self care topics: healthy nutrition; physical activity; coping with stress
(not including mindfulness); sleep hygiene; balancing work and personal life; and living
a drug-free life. Homework was assigned consistent in time with the MBSR group
Amount of contact: Participants in both groups received 8-weekly 2.5-hour sessions
plus a 6-hour session in week 6
Outcomes AQLQchange frombaseline in 2-week averagemorningPEFR, asthma control according
the 2007 NIH/NHLBI guidelines, and PSS. At each assessment, participants recorded
frequency of asthma rescue medication use (short-acting bronchodilators) over a 14-day
period, and days of work or school missed due to asthma. Asthma exacerbations were
assessed by self reported initiation of prednisone in the last 30 days
Follow-up assessments were at 10 weeks, 6 months, and 12 months
Notes Funding: Grant R21 AT002938 (awarded to Drs Pbert and Carmody) from the NIH
National Center for Complementary and Alternative Medicine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Group assignment was by a random allo-
cation scheme with block sizes of four and
six”. Suggests computerised schedule but
unclear
Allocation concealment (selection bias) Low risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The interventions could not be kept blind
from participants and personnel. By de-
fault, this is high risk of bias for subjec-
tive outcomes including self rated ques-
tionnaires, but probably would not intro-
duce bias for more objective outcomes such
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as exacerbations and adverse events. The
study made efforts to ensure the interven-
tion and control were matched in many
ways “to control for as many non-specific
factors as possible”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Assessments occurred at baseline, and at
10 weeks and 6 and 12 months post base-
line by evaluators blind to treatment assign-
ment.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of participants followed up
varied between 37 and 39 out of 42 in the
mindfulness group at different time points
(88% to 93%) and 37 to 41 out of 41 in the
control group (90% to 100%), which rep-
resents low and balanced dropout. “For the
peak flow/medication form and spirome-
try, there were up to 21 missing data points
at follow-up. For short-term rescue medi-
cation use, 2-week average morning PEF,
PEF variability, and FEV1, missing values
were extrapolated using the slope of the two
closest non-missing values; for 10 patients,
single non-missing values were carried for-
ward to all subsequent time points. The
results presented are from these imputed
models.”
Selective reporting (reporting bias) Low risk All of the named outcomes were well re-
ported at all time points and were analysed
as described in the prospectively registered
protocol
Other bias Low risk “Prednisone use differed between groups at
baseline and was included in final models
if associated with time trends and altered
estimates of study arm effects.”
Put 2003
Methods Parallel RCT conducted at a university hospital in Belgium. The intervention lasted for
6 sessions, and measurements were taken at 0, 3, and 6 months
Participants 25 participants were randomised to CBT (13) or the control group (12)
Baseline characteristics: Mean age was 43 (SD 10) in the CBT group and 48 (SD
12) in the control group. Percentage male was 58.3 in the CBT group and 36.4 in the
control group. Participants in the CBT group had a mean percentage predicted FEV1 of
85 (SD 20); those in the control group had a mean of 90 (SD 12). Several other baseline
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characteristics were also reported including duration of symptoms, FEV1 (L), FVC (L)
and %, prescribed medication, and severity of asthma
Baseline psychological status: No information
Inclusion criteria: Diagnosed with asthma at least 6 months earlier
Exclusion criteria: Age younger than 18 or older than 65 years, occupational asthma,
nicotine, drug or alcohol abuse, absence of asthma symptoms during the last 6 months,
brittle asthma, previous participation in an educational or other asthma programme
Interventions Intervention: Individual CBT: psycho-education, behavioural techniques (self observa-
tion/monitoring, stimulus control, response control), cognitive restructuring including
personalised elaboration on problem areas
Delivered by: Trained psychologist
Control: Waiting list
Amount of contact: Participants in the control group received 6 one-hour individual
sessions
Outcomes McMaster AQLQ; ASC; Negative Emotionality Scale; Knowledge, Attitude, and Self-
Efficacy Asthma Questionnaire; Adherence Scale, and PEFR
Notes Funding: Fonds voorWetenschappelijkOnderzoek-Vlaanderen (Grant 7.0004.000) and
Astra Pharmaceuticals, Belgium
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomly allocated to either a programme
group or a waiting list control group by
means of the envelope technique”
Allocation concealment (selection bias) Low risk “This randomisation method consists of
drawing for each subject one unmarked,
non-transparent envelope from a total of
23 envelopes (i.e. number of participants;
12 for treatment and 11 for control condi-
tion) containing the name of either condi-
tion.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The interventions could not be kept blind
from participants and personnel. By de-
fault, this is high risk of bias for subjec-
tive outcomes including self rated question-
naires, but probably would not introduce
bias for more objective outcomes such as
exacerbations and adverse events
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’“Two independent researchers were re-
sponsible for conducting the programme
and for performing the measures. The per-
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son who collected the data was unaware of
the condition each participant was assigned
to.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “From the treatment group, one subject
dropped out after onset of the programme,
(organisational incompatibility with pro-
fessional situation), and from the waiting
list group, not all the datawere collected for
one subject. Eventually, 23 subjects were
included in the study: 12 subjects in the
treatment group, and 11 subjects in the
control group.” Data were not imputed for
non-completers, but unlikely to bias results
since it was only 1 participant per group
Selective reporting (reporting bias) Low risk All of the named outcomes were well re-
ported at all time points and were anal-
ysed as described, although there was no
prospectively registered protocol to check
Other bias Low risk “The control group was prescribed more
anticholinergics than the intervention
group (Chi-squared = 5.3, P = 0.02); both
conditions did not differ regarding other
characteristics. Asthma severity was equal
for both groups, only one subject was cat-
egorised as severely asthmatic.”
Ross 2005
Methods Parallel RCT conducted in Canada. “Participants in the treatment condition were as-
sessed on three occasions: pretreatment, posttreatment, and 6-month follow-up. Partici-
pants in the wait-list conditionwere assessed on four occasions: baseline (which coincided
with the experimental condition pretreatment), pretreatment (which coincided with the
experimental condition posttreatment assessment), posttreatment, and 6-month follow-
up.”
Participants 48 participants were randomised to CBT (25) or the control group (23) (although only
15 and 10, respectively were included in the analysis)
Baseline characteristics: Mean age was 37.9 (SD 10.5) in the CBT group and 40.7
(SD 12.6) in the control group. All participants were female. Mean percentage predicted
FEV1 was 76 (18) pre- and 94 (5) post-bronchodilator for participants in the CBT group
and 81 (16) pre- and 95 (4) post-bronchodilator for those in the control group
Baseline psychological status: Primary diagnosis of panic disorder (determined by
severity) with no, mild, or moderate agoraphobic avoidance, at least 3 panic attacks in
the past 3 weeks
Inclusion criteria: Physician-assigned diagnosis of asthma and who had been referred to
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a pulmonary specialist or who had recently sought ED care for an acute asthma episode, a
primary diagnosis of panic disorder (determined by severity) with no, mild, or moderate
agoraphobic avoidance, at least 3 panic attacks in the past 3 weeks
Exclusion criteria: Recent change in psychotropic medication type or dose, medical
condition that would contraindicate protocol participation or that would confuse the
interpretation of the results, for example emphysema, organic brain syndrome, bipolar
disorder, schizophrenia, obsessive-compulsive disorder, and alcohol or drug dependence
Interventions Intervention: Derived from Barlow panic control treatment and Beck cognitive treat-
ment for panic disorder. The CBT portion included education about the nature, eti-
ology, and maintenance of anxiety and panic, cognitive therapy techniques, training in
slow diaphragmatic breathing, and interoceptive exposure exercises. The asthma educa-
tion program consisted of information about airways inflammation and bronchospasm,
rescue and controller medication, methods of self monitoring, triggers, action plans,
reviewing asthma diaries, and the overlap/interplay of asthma and panic. Delivered by 2
nurse clinicians in small groups of 3 to 5 participants
Delivered by: 2 doctorally prepared nurse clinicians, 1 trained as an asthma educator
and 1 with postdoctoral training in CBT
Control: No treatment. Participants were offered the intervention after the study had
finished
Amount of contact: Participants in the treatment group received 12 90-minute sessions
over 8 weeks. Sessions 1 through 8 were conducted twice weekly, and sessions 9 through
12 were spaced 1 week apart
Outcomes Panic attack diary, SPRAS, ASI, FQ-Ago, BDI, asthma symptom-free days, morning
PEFR, and peak-flow variability from Asthma Symptom Diaries, AQLQ
Notes Funding: Funded in part by the Alberta Heritage Foundation for Medical Research, the
Alberta Lung Association, and the Canadian Lung Association
Due to the design of the study, we extracted data at post-treatment for the experimental
group and at pre-treatment for the control group (i.e. after randomisation but before
they were also given the intervention)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Describes in detail how participants were
screened over the phone but not the sched-
ule for randomisation, just “randomly allo-
cated”
Allocation concealment (selection bias) Unclear risk Does not state who actually assigned the
participants to groups and how
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The interventions could not be kept blind
from participants and personnel. By de-
fault, this is high risk of bias for subjec-
tive outcomes including self rated question-
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naires, but probably would not introduce
bias for more objective outcomes such as
exacerbations and adverse events
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors could have been blind,
but there was no description in the study
of whether or how this was done
Incomplete outcome data (attrition bias)
All outcomes
High risk “48 participants were offered and accepted
a place in the CBT-AE program and were
randomly assigned to either the experimen-
tal treatment condition (n=24) or thewait-
list condition (n = 24). Fourteen of these
participants (11 in the wait-list condition)
dropped out prior to treatment, leaving 34
who commenced treatment. Nine of these
34 participants withdrew from treatment
for a variety of reasons unrelated to treat-
ment.” Outcomes and demographic char-
acteristics are reported for the remaining 25
(15 experimental, 10 control) participants
and not for the whole sample
Selective reporting (reporting bias) Low risk All outcomes reported in appropriate de-
tail.
Other bias Low risk “When these pretreatment dropouts (n =
14) were compared with the treatment
completers (n = 25), using t-tests or chi
squares where appropriate, no significant
between-group differences were found on
any of the demographic variables (age,mar-
ital status, education, income) or any of the
clinical variables (self-rated asthma severity,
years since asthma diagnosis, average num-
ber of asthma medications, average num-
ber of comorbid anxiety disorders, propor-
tion on psychotropic medications, or other
medications). Moreover, separate analyses
revealed no significant between-group dif-
ferences on the SPRAS, FQ-Ago, ASI, BDI,
and AQLQ scores obtained at baseline (in
the case of participants assigned to the wait-
list condition) or pretreatment (in the case
of participants assigned to the experimen-
tal treatment condition).”
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Methods Parallel RCT conducted at a medical centre in Italy.Measurements were taken at baseline
while participants were admitted to hospital and a year later
Participants 40 participants were randomised to CBT (20) or the control group (20)
Baseline characteristics: Mean age was 44 (SD 16) in the CBT group and 51 (SD 16)
in the control group. Percentage male was 55 in the CBT group and 45 in the control
group.Mean percentage predicted FEV1 was 76 (SD 18) pre-bronchodilator and 94 (SD
5) post-bronchodilator for the CBT group, and 81 (SD 16) pre-bronchodilator and 95
(SD 4) post-bronchodilator for the control group. Several other baseline characteristics
were also reported, including mean duration of asthma diagnosis
Baseline psychological status: No information
Inclusion criteria: Asthma diagnosed, treated, and followed up according to 1987Amer-
ican Thoracic Society guidelines
Exclusion criteria: Not well described
Interventions Intervention: ARG: Educational programme consisting of meetings (twice in hospi-
tal and quarterly throughout the following year) with physician, physiotherapist and
psychologist, daily peak flow meter, telephone access to physician, personal medication
plan, followed up 6 times a year by the physician. CBT intervention was given during
3 individual meetings with the psychologist covering cognitive restructuring, education
on symptoms and emotional reactions to them, behaviour modification, use of drugs
and psychological aspects of anxiety, relaxation training
Delivered by: Trained psychologist
Control: The control group did not receive an educational programme or psychological
intervention. They were treated according to NHLBI 1991 guidelines and followed up
6 times/year by the physician with examination and spirometry
Amount of contact: 6 educational sessions (2 in hospital and 4 out of hospital) + 3
sessions of CBT + 6 physician visits. The control just received 6 physician visits
Outcomes STAI, QD, QPF (not defined but described as assessing psychophysiological disorders,
as part of the Cognitive Behavioural Assessment), ASC in Italian to assess the emotional
reactions to asthmatic crises (i.e. panic-fear), Respiratory Illness Opinion Survey in Ital-
ian, Health Locus of Control Scale in Italian, plus clinical interview. All at baseline and
1 year later
Notes Funding: No information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The patientswere randomly assigned to an
Asthma Rehabilitation Group…or a Con-
trol Group.”
Allocation concealment (selection bias) Unclear risk ’“Forty consecutive patientswere enrolled”;
no other details provided
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk The interventions could not be kept blind
from participants and personnel. By de-
fault, this is high risk of bias for subjec-
tive outcomes including self rated question-
naires, but probably would not introduce
bias for more objective outcomes such as
exacerbations and adverse events
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors could have been blind,
but there was no description in the study
of whether or how this was done
Incomplete outcome data (attrition bias)
All outcomes
High risk ’“No patients from the ARG dropped out
of the study, whilst four (20%) of the CG
dropped out during the follow-up”
Selective reporting (reporting bias) High risk Key clinical outcomes only reported in
detail at baseline (attacks, hospitalisation
days, emergency visits, andwork/school ab-
sences). Also, ASC “not considered because
seven patients from the AR had no further
asthmatic crises in the period following en-
rolment, thus making the compilation of
the test at follow-up, and statistical com-
parison, impossible”
Other bias High risk The intervention group received additional
interventions, whichmay have confounded
the result
Yorke 2013
Methods Parallel RCT conducted at 2 tertiary hospitals in England. The intervention lasted for 8
weeks, and measurements were taken at 0, 8, and 16 weeks
Participants 51 participants were randomised to CBT (25) or the control group (26)
Baseline characteristics: Mean age was 48.6 (SD 11.1) in the CBT group and 45.0
(SD 13.7) in the control group. Percentage male was 35 in the CBT group and 52
in the control group. Several other baseline characteristics were also reported including
ethnicity, previous counselling,HADS, AQLQ,ACQ,D12, andEuroQol baseline scores
Baseline psychological status: HADS score > 8 for either subscale
Inclusion criteria: Participants from 2 tertiary hospitals in England attending 1 of a
small subgroup of national specialist severe asthma clinics were screened for the following
eligibility criteria: adults (≥ 18 years of age) with a confirmed diagnosis of severe refrac-
tory asthma (ATS 2000) and receiving standard-of-care therapy at BTS Steps 4 and 5
level. Participants were routinely screened for the presence of clinically significant anxiety
or depression, or both using the HADS (score > 8 for anxiety or > 8 for depression)
Exclusion criteria: People with a specific psychiatric condition (e.g. schizophrenia, hy-
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pomania)
Interventions Intervention: Manual-guided group CBT (Antoni) with focus on relaxed breathing for
anxiety-related breathlessness and personal goal-setting, with a CD to help participants
practice relaxation between sessions. Topics covered included stress and awareness of
asthma exacerbations, linking thoughts and emotions, cognitive distortions, building
resilience/coping strategies, problem-solving, communication, and social support
Delivered by: Trained clinical psychology therapists
Control: Usual care only
Amount of contact: Participants in the CBT group received 8 1.5-hour weekly sessions.
Control group participants did not receive any additional contact
Outcomes AQLQ, ACQ, HADS, asthma diary, acceptability, D12, EQ-5D, and EQ-VAS
Notes Funding: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was carried out indepen-
dently by the Clinical Trials and Evaluation
Unit (CTEU), Royal Brompton and Hare-
field National Health Service Foundation
Trust (RBHT)
Allocation concealment (selection bias) Low risk Randomisation was carried out indepen-
dently by the Clinical Trials and Evaluation
Unit (CTEU), Royal Brompton and Hare-
field National Health Service Foundation
Trust (RBHT)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The interventions could not be kept blind
from participants and personnel. By de-
fault, this is high risk of bias for subjec-
tive outcomes including self rated question-
naires, but probably would not introduce
bias for more objective outcomes such as
exacerbations and adverse events
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Data collection-design facilitated research
nurse (RN) blinding to group allocation,
however this was difficult to maintain as
participants often discussed their treatment
with the RN at subsequent study follow-
ups
46Cognitive behavioural therapy (CBT) for adults and adolescents with asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Yorke 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk ’“Seven subjects (3 G-CBT and 4 control)
who undertook the study were later found
not to meet the inclusion criteria, and were
removed from all analyses, leaving 44 (from
51 randomised). Participants allocated to
receiveG-CBT but withdrew prior to start-
ing treatment (n = 3) or provided baseline
data only (n = 2; attended 2 or less sessions)
were removed from further analyses. For
each variable there was less than 10%miss-
ing data. The only exception was asthma
diaries (discussed below).” Numbers in the
outcome table are 13 and 18-19
Selective reporting (reporting bias) Low risk All of the named outcomes were well re-
ported at all time points and were analysed
as described in the published reports or via
the study author (JY)
Other bias Low risk None noted.
ABP = Asthma Bother Profile
ACQ = Asthma Control Questionnaire
AMHLC = Asthma Multidimensional Health Locus of Control
ANCOVA = analysis of covariance
AQLQ = Asthma Quality of Life Questionnaire
ARG = Asthma Rehabilitation Group
ASC-PF = Asthma Symptom Checklist Panic-Fear subscale
ASI = Anxiety Sensitivity Index
ASMP = asthma self management program
BDI = Beck Depression Inventory
BTS = British Thoracic Society
CBT = cognitive behavioural therapy
D12 = Dyspnoea-12 questionnaire
ED = emergency department
EQ-5D = EuroQol 5D
EQ-VAS = EuroQol visual analogue scale
FEV1 = forced expiratory volume in one second
FQ-Ago = Fear Questionnaire - Agoraphobia subscale
FVC = forced vital capacity
HADS = Hospital Anxiety and Depression Scale
HLC = Healthy Living Course
MBSR = Mindfulness-Based Stress Reduction
NCT = National Clinical Trials (clinicaltrials.gov)
NIH/NHLBI = National Institutes of Health/National Heart, Lung, and Blood Institute
PEFR = peak expiratory flow rate
PSS = Perceived Stress Scale
RCT = randomised controlled trial
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SD = standard deviation
SPRAS = Sheehan Patient-Rated Anxiety Scale
SSIS = semi-structured interview schedule
STAI = State-Trait Anxiety Inventory
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ACTRN12613000675729 Wrong population - children
Bailey 1987 Wrong design - not an RCT. Not CBT
Balfour 1957 Wrong design - not an RCT
Baptist 2013 Wrong intervention - self management
Barendregt 1957 Wrong design - not an RCT
Benedito 1996 Wrong intervention and comparison - 3 non-CBT therapies and no usual care comparator
Bosley 1995 Wrong design - allocation not random
Charlson 2007 Wrong intervention and mixed population - purely behavioural
Chen 2010 Wrong intervention - self efficacy
ChiCTR-COC-15007442 Wrong design - case-control study
Clark 2004 Wrong intervention - self management
Deenen 1996 Wrong population - severe asthma and COPD. Data for those with asthma not available separately
Deter 1983 Wrong intervention - purely relaxation therapy rather than full CBT
Epstein 2004 Wrong intervention - mental imagery
Hampel 2003 Wrong population - children and adolescents with a mean age of 11.6
Hock 1978 Wrong population and intervention - children and not CBT
Holloway 2007 Wrong intervention - Papworth breathing techniques
Jerant 2008 Wrong intervention and mixed population - not testing CBT
Khoshnavay 2013 Wrong population - children
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(Continued)
Kotses 1995a Wrong intervention - self management
Lewandowska 2006 Wrong design - not randomly allocated
Mancuso 2010 Wrong intervention - self management education
Mancuso 2012 Wrong intervention - self efficacy not CBT
Miklich 1977 Wrong design - not randomly allocated
Mildenhall 1997 Wrong intervention - coping skills program
Milenkovi 2007 Wrong intervention - self management program
Moore 1965 Wrong design and intervention - within-patient comparison and solely behavioural intervention
Perrin 1992 Wrong population - children
Philipp 1972 Wrong design - not an RCT
Sanger 1969 Wrong intervention and design - not a CBT intervention and unlikely to be an RCT
Smith 2005 Wrong intervention - psycho-education
Smith 2015 Wrong intervention - written emotional disclosure
Song 2005 Wrong intervention - mostly relaxation, and not properly randomised
Spiess 1988 Wrong intervention - “information and relaxation groups”
Srof 2012 Wrong intervention - self efficacy
Stone 2000 Wrong intervention - written emotional disclosure
Theadom 2010 Wrong intervention - written emotional disclosure
Tong 2002 Wrong population - children
van Gaalen 2013 Wrong intervention - internet-based management support
Vazquez 1993 Wrong intervention - relaxation therapy
Vazquez 1993a Wrong intervention - relaxation therapy
Wilkening 1999 Wrong intervention - only behavioural elements
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CBT = cognitive behavioural therapy
COPD = chronic obstructive pulmonary disease
RCT = randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
ACTRN12614000915651
Trial name or title Randomised controlled trial of telephone based CBT for patients with chronic lung disease and anxiety
and/or depression undergoing pulmonary rehabilitation to evaluate the effect on symptoms of anxiety and
depression, quality of life, and exacerbations
Methods Parallel randomised control trial
Participants Mixed population with chronic lung disease - may not meet inclusion criteria
Interventions Intervention will be 6 CBT sessions administered by psychology interns. The 6 sessions will include 2
individual face-to-face sessions (an hour each, within the first 4 weeks of pulmonary rehabilitation) and 4
phone sessions (an hour each, fortnightly within the first 2 months after the face-to-face sessions).
The comparator will be usual care comprised of medical treatment and pulmonary rehabilitation
Outcomes Primary outcomes: Symptoms of anxiety using GAI; symptoms of depression using GDS
Secondary outcomes: 6MWD; SGRQ; asthma patients will also answer the AQLQ and ACQ; emergent
healthcare utilisation (primary care and hospital care) assessed by data linkage to patient medical records and
a questionnaire (designed for this study to assess exacerbation rate) at 6- and 12-month intervals.
Pulmonary rehabilitation attendance and a structured interview aimed to assess participation
Starting date Not yet recruiting
Contact information Professor Ian Yang and Dr Marsus I Pumar, both at The Prince Charles Hospital, Queensland Australia
Notes www.anzctr.org.au/ACTRN12614000915651.aspx
apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12614000915651
IRCT2015061622770N1
Trial name or title The impact of mindfulness-based cognitive therapy on anxiety and depression and somatic symptoms in
patients with asthma
Methods Randomly allocated to intervention and control groups using sealed envelopes. Not blind. Parallel
“This project is an empirical study of pre- and post-test.”
Sample size 30
Random participants in the control group or the experiment will be replaced
Participants Inclusion criteria: Women aged 55 to 18, at least 1 year since asthma diagnosis, high school education or
above, ongoing medical treatment
Exclusion criteria: Risk for psychotic disorder or other physical illness and absenteeism on more than 2
treatment sessions
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IRCT2015061622770N1 (Continued)
Interventions Interventions: Mindfulness-based cognitive therapy, 2-hour sessions, 8 sessions per week
Control group: Placed on a waiting list and will not receive any intervention
Outcomes The instruments included Beck Depression Inventory, the Beck Anxiety Inventory, and AQLQ
Measured before and immediately after the intervention.
Starting date April 2015 - retrospective registration
Contact information Dr Ramani Ghasemi, Asthma Clinic, Jesus son of Mary Hospital, Esfahan, Iran
Notes apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2015061622770N1
NCT01583296
Trial name or title Adaptation of a behavioral treatment for Latinos with panic disorder and asthma
Methods Parallel, double-blind randomised controlled trial
Participants Enrolment 53
Interventions Intervention: CBT and heart rate variability biofeedback
Control group: Music Relaxation Therapy (may not meet the review inclusion criteria as not usual care)
Outcomes Primary: Panic disorder severity scale and use of quick-relief medication for asthma
Secondary: ACQ, Clinical Global Impression Scale, adherence with controller medications for asthma
All measured as change from pre-intervention to post-intervention (8 weeks)
Starting date July 2010
Contact information Jonathan Feldman, Albert Einstein College of Medicine of Yeshiva University
Notes clinicaltrials.gov/ct2/show/NCT01583296
6MWD = 6-minute walk distance
ACQ = Asthma Control Questionnaire
AQLQ = Asthma Quality of Life Questionnaire
CBT = cognitive behavioural therapy
GAI = Geriatric Anxiety Inventory
GDS = Geriatric Depression scale
SGRG = St George’s Respiratory Questionnaire
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D A T A A N D A N A L Y S E S
Comparison 1. Cognitive behavioural therapy versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Asthma-related quality of life
(AQLQ) primary endpoint
6 214 Mean Difference (IV, Random, 95% CI) 0.55 [0.17, 0.93]
2 Asthma-related quality of life
(AQLQ) follow-up
3 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 3 months 1 12 Mean Difference (IV, Random, 95% CI) 1.08 [0.41, 1.74]
2.2 6 months 2 106 Mean Difference (IV, Random, 95% CI) 0.51 [0.05, 0.97]
2.3 12 months 1 83 Mean Difference (IV, Random, 95% CI) 0.66 [0.30, 1.02]
3 Asthma control 3 95 Std. Mean Difference (IV, Random, 95% CI) -0.98 [-1.76, -0.20]
4 Unscheduled healthcare visits 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 GP visits 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Primary care visits 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Anxiety scales 6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Anxiety change scores 3 185 Std. Mean Difference (IV, Random, 95% CI) -0.38 [-0.73, -0.03]
5.2 Anxiety endpoint scores 3 142 Std. Mean Difference (IV, Random, 95% CI) -0.25 [-1.02, 0.51]
5.3 Anxiety & depression
change scores
2 72 Std. Mean Difference (IV, Random, 95% CI) -0.62 [-1.84, 0.59]
6 Depression scales 5 Std. Mean Difference (Fixed, 95% CI) Subtotals only
6.1 Depression change scores 2 112 Std. Mean Difference (Fixed, 95% CI) -0.33 [-0.70, 0.05]
6.2 Depression endpoint
scores
3 83 Std. Mean Difference (Fixed, 95% CI) -0.41 [-0.87, 0.05]
7 Medication adherence 1 23 Mean Difference (IV, Random, 95% CI) -1.40 [-2.94, 0.14]
Comparison 2. Subgroup analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Individual vs group CBT: AQLQ 6 214 Mean Difference (IV, Random, 95% CI) 0.55 [0.17, 0.93]
1.1 Individual 2 63 Mean Difference (IV, Random, 95% CI) 0.78 [0.33, 1.23]
1.2 Group 4 151 Mean Difference (IV, Random, 95% CI) 0.41 [-0.11, 0.93]
2 Baseline psychology: AQLQ 6 214 Mean Difference (IV, Random, 95% CI) 0.55 [0.17, 0.93]
2.1 Psychological symptoms 3 68 Mean Difference (IV, Random, 95% CI) 0.49 [-0.38, 1.36]
2.2 No psychological
symptoms
3 146 Mean Difference (IV, Random, 95% CI) 0.57 [0.13, 1.01]
3 CBT models: AQLQ 6 214 Mean Difference (IV, Random, 95% CI) 0.55 [0.17, 0.93]
3.1 Classic CBT 5 131 Mean Difference (IV, Random, 95% CI) 0.64 [0.19, 1.10]
3.2 MBSR 1 83 Mean Difference (IV, Random, 95% CI) 0.27 [-0.09, 0.63]
52Cognitive behavioural therapy (CBT) for adults and adolescents with asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 Cognitive behavioural therapy versus usual care, Outcome 1 Asthma-related
quality of life (AQLQ) primary endpoint.
Review: Cognitive behavioural therapy (CBT) for adults and adolescents with asthma
Comparison: 1 Cognitive behavioural therapy versus usual care
Outcome: 1 Asthma-related quality of life (AQLQ) primary endpoint
Study or subgroup CBT Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Deshmukh 2008 (1) 0.62222 (1.15518) 9 3 -0.4 (0.264575) 13.2 % 1.02 [ 0.21, 1.83 ]
Grover 2007 (2) 20 2.13 (0.98) 20 1.59 (0.86) 19.0 % 0.54 [ -0.03, 1.11 ]
Pbert 2012 (3) 42 0.51 (0.8343) 41 0.24 (0.8237) 25.8 % 0.27 [ -0.09, 0.63 ]
Put 2003 (4) 12 5.7 (0.6) 11 4.7 (0.7) 20.0 % 1.00 [ 0.46, 1.54 ]
Ross 2005 (5) 15 5.07 (1.2) 9 4.25 (1.13) 10.7 % 0.82 [ -0.14, 1.78 ]
Yorke 2013 (6) 13 -0.2 (1.5) 19 0.2 (0.9) 11.4 % -0.40 [ -1.31, 0.51 ]
Total (95% CI) 111 103 100.0 % 0.55 [ 0.17, 0.93 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 10.74, df = 5 (P = 0.06); I2 =53%
Test for overall effect: Z = 2.84 (P = 0.0045)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours usual care Favours CBT
to 0.90)
(1) Deshmukh data were calculated from individual patient data on a poster graph provided by the study authors.
(2) Change from baseline. 8 week endpoint.
(3) Change from baseline. 10 week endpoint (6 and 12 month follow-up data reported narratively). Absolute scores were also reported and changed the pooled result
to MD 0.42, 95% CI -0.06
(4) Endpoint scores at end of treatment (3 months). 6 month follow up also available and reported narratively.
(5) Endpoint scores. Post 8 week treatment, or pre-treatment in control (8 weeks after baseline and before controls started treatment)
(6) Change from baseline, 16 weeks
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Analysis 1.2. Comparison 1 Cognitive behavioural therapy versus usual care, Outcome 2 Asthma-related
quality of life (AQLQ) follow-up.
Review: Cognitive behavioural therapy (CBT) for adults and adolescents with asthma
Comparison: 1 Cognitive behavioural therapy versus usual care
Outcome: 2 Asthma-related quality of life (AQLQ) follow-up
Study or subgroup CBT Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 3 months
Deshmukh 2008 0.67778 (0.749629) 9 3 -0.4 (0.4) 100.0 % 1.08 [ 0.41, 1.74 ]
Subtotal (95% CI) 9 3 100.0 % 1.08 [ 0.41, 1.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.17 (P = 0.0015)
2 6 months
Pbert 2012 42 0.6 (0.7381) 41 0.28 (0.7287) 60.3 % 0.32 [ 0.00, 0.64 ]
Put 2003 12 5.7 (0.7) 11 4.9 (0.6) 39.7 % 0.80 [ 0.27, 1.33 ]
Subtotal (95% CI) 54 52 100.0 % 0.51 [ 0.05, 0.97 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 2.32, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 2.17 (P = 0.030)
3 12 months
Pbert 2012 42 0.72 (0.8343) 41 0.06 (0.8237) 100.0 % 0.66 [ 0.30, 1.02 ]
Subtotal (95% CI) 42 41 100.0 % 0.66 [ 0.30, 1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.63 (P = 0.00029)
Test for subgroup differences: Chi2 = 1.90, df = 2 (P = 0.39), I2 =0.0%
-2 -1 0 1 2
Favours usual care Favours CBT
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Analysis 1.3. Comparison 1 Cognitive behavioural therapy versus usual care, Outcome 3 Asthma control.
Review: Cognitive behavioural therapy (CBT) for adults and adolescents with asthma
Comparison: 1 Cognitive behavioural therapy versus usual care
Outcome: 3 Asthma control
Study or subgroup CBT Usual care
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Grover 2007 (1) 20 -21.95 (6.9) 20 -11.95 (4.7) 34.4 % -1.66 [ -2.39, -0.93 ]
Put 2003 (2) 12 2.4 (0.9) 11 3.2 (0.8) 30.6 % -0.90 [ -1.77, -0.04 ]
Yorke 2013 (3) 13 -0.2 (1) 19 0.2 (1.1) 34.9 % -0.37 [ -1.08, 0.34 ]
Total (95% CI) 45 50 100.0 % -0.98 [ -1.76, -0.20 ]
Heterogeneity: Tau2 = 0.32; Chi2 = 6.22, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours CBT Favours usual care
(1) Means were reported as positives in the paper but states that lower scores are better and that more improvement was seen in the CBT group.
(2) ASC scores at 12 weeks
(3) ACQ change from baseline to week 16
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Analysis 1.4. Comparison 1 Cognitive behavioural therapy versus usual care, Outcome 4 Unscheduled
healthcare visits.
Review: Cognitive behavioural therapy (CBT) for adults and adolescents with asthma
Comparison: 1 Cognitive behavioural therapy versus usual care
Outcome: 4 Unscheduled healthcare visits
Study or subgroup CBT Usual care
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 GP visits
Parry 2012 (1) 41 1.8 (1.5) 39 2.08 (3.1) -0.28 [ -1.36, 0.80 ]
2 Primary care visits
Parry 2012 (2) 41 1.87 (1.73) 39 2.27 (3.1) -0.40 [ -1.51, 0.71 ]
-2 -1 0 1 2
Favours CBT Favours usual care
(1) in the 6 months after treatment
(2) (inc nurse and out-of-hours visits)
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Analysis 1.5. Comparison 1 Cognitive behavioural therapy versus usual care, Outcome 5 Anxiety scales.
Review: Cognitive behavioural therapy (CBT) for adults and adolescents with asthma
Comparison: 1 Cognitive behavioural therapy versus usual care
Outcome: 5 Anxiety scales
Study or subgroup CBT Usual care
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Anxiety change scores
Parry 2012 (1) 41 -1 (3.71) 39 1.1 (3.91) 40.8 % -0.55 [ -0.99, -0.10 ]
Pbert 2012 (2) 36 -4.3 (5.6155) 37 -1.5 (5.9985) 38.6 % -0.48 [ -0.94, -0.01 ]
Yorke 2013 (3) 13 -2 (3.2) 19 -2.6 (4.7) 20.6 % 0.14 [ -0.57, 0.85 ]
Subtotal (95% CI) 90 95 100.0 % -0.38 [ -0.73, -0.03 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 2.76, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 2.10 (P = 0.035)
2 Anxiety endpoint scores
Parry 2012 (4) 42 24.19 (9.75) 40 28.05 (8.25) 38.8 % -0.42 [ -0.86, 0.02 ]
Ross 2005 (5) 15 31.73 (22.29) 9 57.56 (31.56) 28.1 % -0.96 [ -1.84, -0.08 ]
Sommaruga 1995 20 36.7 (9.1) 16 32.4 (5.6) 33.1 % 0.54 [ -0.13, 1.21 ]
Subtotal (95% CI) 77 65 100.0 % -0.25 [ -1.02, 0.51 ]
Heterogeneity: Tau2 = 0.35; Chi2 = 8.45, df = 2 (P = 0.01); I2 =76%
Test for overall effect: Z = 0.65 (P = 0.52)
3 Anxiety % depression change scores
Grover 2007 (6) 20 -11.1 (5.2) 20 -4.65 (5) 50.3 % -1.24 [ -1.92, -0.56 ]
Yorke 2013 13 -4.3 (5.2) 19 -4.3 (7.6) 49.7 % 0.0 [ -0.71, 0.71 ]
Subtotal (95% CI) 33 39 100.0 % -0.62 [ -1.84, 0.59 ]
Heterogeneity: Tau2 = 0.64; Chi2 = 6.12, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 0.26, df = 2 (P = 0.88), I2 =0.0%
-2 -1 0 1 2
Favours CBT Favours usual care
was seen in the CBT group.
(1) ASC panic/fear change from baseline
(2) Change from baseline to 10 weeks (after treatment) on the Perceived Stress Scale. N per arm not given so split total.
(3) HADS-Anxiety change from baseline to week 16 endpoint
(4) ASC panic/fear at end of study
(5) 8 week scores on the Sheehan Patient Rated Anxiety Scale (SPRAS)
(6) Change from baseline to 8 weeks on the joint HADS anxiety and depression. Means were reported as positives in the paper but states that lower scores are better
and that more improvement
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Analysis 1.6. Comparison 1 Cognitive behavioural therapy versus usual care, Outcome 6 Depression scales.
Review: Cognitive behavioural therapy (CBT) for adults and adolescents with asthma
Comparison: 1 Cognitive behavioural therapy versus usual care
Outcome: 6 Depression scales
Study or subgroup CBT Usual care
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Depression change scores
Parry 2012 (1) 41 39 -0.3899 (0.2231) 72.3 % -0.39 [ -0.83, 0.05 ]
Yorke 2013 (2) 13 19 -0.1581 (0.3606) 27.7 % -0.16 [ -0.86, 0.55 ]
Subtotal (95% CI) 54 58 100.0 % -0.33 [ -0.70, 0.05 ]
Heterogeneity: Chi2 = 0.30, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.086)
2 Depression endpoint scores
Put 2003 (3) 12 11 -1.6491 (0.4956) 22.2 % -1.65 [ -2.62, -0.68 ]
Ross 2005 (4) 15 9 -0.5204 (0.4296) 29.6 % -0.52 [ -1.36, 0.32 ]
Sommaruga 1995 (5) 20 16 0.2315 (0.3367) 48.2 % 0.23 [ -0.43, 0.89 ]
Subtotal (95% CI) 47 36 100.0 % -0.41 [ -0.87, 0.05 ]
Heterogeneity: Chi2 = 9.95, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
-2 -1 0 1 2
Favours CBT Favours usual care
scores than the delayed treatment group at baseline which might lead to an underestimation of the treatment effect)
(1) Hospital Anxiety and Depression Scale, depression subscale. Change from baseline to 3 months
(2) Hospital Anxiety and Depression Scale, depression sub-scale. Change from baseline to 16 weeks.
(3) Negatie Emotionality Score at 3 months. Six month follow up reported narratively.
(4) Beck Depression Inventory after 8 weeks of treatment (or pre-treatment measure for control group before they commenced therapy). Some baseline differences
(experimental group had worse
(5) Depression Questionnaire in Italian. Endpoint scores at 52 weeks.
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Analysis 1.7. Comparison 1 Cognitive behavioural therapy versus usual care, Outcome 7 Medication
adherence.
Review: Cognitive behavioural therapy (CBT) for adults and adolescents with asthma
Comparison: 1 Cognitive behavioural therapy versus usual care
Outcome: 7 Medication adherence
Study or subgroup CBT Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Put 2003 (1) 12 7 (1.6) 11 8.4 (2.1) 100.0 % -1.40 [ -2.94, 0.14 ]
Total (95% CI) 12 11 100.0 % -1.40 [ -2.94, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours CBT Favours usual care
and 6 months after which is also reported narratively.
(1) Adherence scale at 3 months. Also measured at 6 month follow-up which is reported narratively. Parry 2012 reported the number of prescriptions taken 6 months
before treatment, during,
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Analysis 2.1. Comparison 2 Subgroup analyses, Outcome 1 Individual vs group CBT: AQLQ.
Review: Cognitive behavioural therapy (CBT) for adults and adolescents with asthma
Comparison: 2 Subgroup analyses
Outcome: 1 Individual vs group CBT: AQLQ
Study or subgroup CBT Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Individual
Grover 2007 (1) 20 2.13 (0.98) 20 1.59 (0.86) 19.0 % 0.54 [ -0.03, 1.11 ]
Put 2003 (2) 12 5.7 (0.6) 11 4.7 (0.7) 20.0 % 1.00 [ 0.46, 1.54 ]
Subtotal (95% CI) 32 31 39.0 % 0.78 [ 0.33, 1.23 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.33, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 3.40 (P = 0.00067)
2 Group
Deshmukh 2008 (3) 0.62222 (1.15518) 9 3 -0.4 (0.264575) 13.2 % 1.02 [ 0.21, 1.83 ]
Pbert 2012 (4) 42 0.51 (0.8343) 41 0.24 (0.8237) 25.8 % 0.27 [ -0.09, 0.63 ]
Ross 2005 (5) 15 5.07 (1.2) 9 4.25 (1.13) 10.7 % 0.82 [ -0.14, 1.78 ]
Yorke 2013 (6) 13 -0.2 (1.5) 19 0.2 (0.9) 11.4 % -0.40 [ -1.31, 0.51 ]
Subtotal (95% CI) 79 72 61.0 % 0.41 [ -0.11, 0.93 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 6.36, df = 3 (P = 0.10); I2 =53%
Test for overall effect: Z = 1.53 (P = 0.13)
Total (95% CI) 111 103 100.0 % 0.55 [ 0.17, 0.93 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 10.74, df = 5 (P = 0.06); I2 =53%
Test for overall effect: Z = 2.84 (P = 0.0045)
Test for subgroup differences: Chi2 = 1.12, df = 1 (P = 0.29), I2 =11%
-2 -1 0 1 2
Favours usual care Favours CBT
to 0.90)
(1) Change from baseline. 8 week endpoint.
(2) Endpoint scores at end of treatment (3 months). 6 month follow up also available and reported narratively.
(3) Deshmukh data were calculated from individual patient data on a poster graph provided by the study authors.
(4) Change from baseline. 10 week endpoint (6 and 12 month follow-up data reported narratively). Absolute scores were also reported and changed the pooled result
to MD 0.42, 95% CI -0.06
(5) Endpoint scores. Post 8 week treatment, or pre-treatment in control (8 weeks after baseline and before controls started treatment)
(6) Change from baseline, 16 weeks
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Analysis 2.2. Comparison 2 Subgroup analyses, Outcome 2 Baseline psychology: AQLQ.
Review: Cognitive behavioural therapy (CBT) for adults and adolescents with asthma
Comparison: 2 Subgroup analyses
Outcome: 2 Baseline psychology: AQLQ
Study or subgroup CBT Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Psychological symptoms
Deshmukh 2008 (1) 0.62222 (1.15518) 9 3 -0.4 (0.264575) 13.2 % 1.02 [ 0.21, 1.83 ]
Ross 2005 (2) 15 5.07 (1.2) 9 4.25 (1.13) 10.7 % 0.82 [ -0.14, 1.78 ]
Yorke 2013 (3) 13 -0.2 (1.5) 19 0.2 (0.9) 11.4 % -0.40 [ -1.31, 0.51 ]
Subtotal (95% CI) 37 31 35.2 % 0.49 [ -0.38, 1.36 ]
Heterogeneity: Tau2 = 0.39; Chi2 = 5.77, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 1.10 (P = 0.27)
2 No psychological symptoms
Grover 2007 (4) 20 2.13 (0.98) 20 1.59 (0.86) 19.0 % 0.54 [ -0.03, 1.11 ]
Pbert 2012 (5) 42 0.51 (0.8343) 41 0.24 (0.8237) 25.8 % 0.27 [ -0.09, 0.63 ]
Put 2003 (6) 12 5.7 (0.6) 11 4.7 (0.7) 20.0 % 1.00 [ 0.46, 1.54 ]
Subtotal (95% CI) 74 72 64.8 % 0.57 [ 0.13, 1.01 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 4.97, df = 2 (P = 0.08); I2 =60%
Test for overall effect: Z = 2.55 (P = 0.011)
Total (95% CI) 111 103 100.0 % 0.55 [ 0.17, 0.93 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 10.74, df = 5 (P = 0.06); I2 =53%
Test for overall effect: Z = 2.84 (P = 0.0045)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
-2 -1 0 1 2
Favours usual care Favours CBT
to 0.90)
(1) Deshmukh data were calculated from individual patient data on a poster graph provided by the study authors.
(2) Endpoint scores. Post 8 week treatment, or pre-treatment in control (8 weeks after baseline and before controls started treatment)
(3) Change from baseline, 16 weeks
(4) Change from baseline. 8 week endpoint.
(5) Change from baseline. 10 week endpoint (6 and 12 month follow-up data reported narratively). Absolute scores were also reported and changed the pooled result
to MD 0.42, 95% CI -0.06
(6) Endpoint scores at end of treatment (3 months). 6 month follow up also available and reported narratively.
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Analysis 2.3. Comparison 2 Subgroup analyses, Outcome 3 CBT models: AQLQ.
Review: Cognitive behavioural therapy (CBT) for adults and adolescents with asthma
Comparison: 2 Subgroup analyses
Outcome: 3 CBT models: AQLQ
Study or subgroup CBT Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Classic CBT
Deshmukh 2008 (1) 0.62222 (1.15518) 9 3 -0.4 (0.264575) 13.2 % 1.02 [ 0.21, 1.83 ]
Grover 2007 (2) 20 2.13 (0.98) 20 1.59 (0.86) 19.0 % 0.54 [ -0.03, 1.11 ]
Put 2003 (3) 12 5.7 (0.6) 11 4.7 (0.7) 20.0 % 1.00 [ 0.46, 1.54 ]
Ross 2005 (4) 15 5.07 (1.2) 9 4.25 (1.13) 10.7 % 0.82 [ -0.14, 1.78 ]
Yorke 2013 (5) 13 -0.2 (1.5) 19 0.2 (0.9) 11.4 % -0.40 [ -1.31, 0.51 ]
Subtotal (95% CI) 69 62 74.2 % 0.64 [ 0.19, 1.10 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 7.78, df = 4 (P = 0.10); I2 =49%
Test for overall effect: Z = 2.79 (P = 0.0053)
2 MBSR
Pbert 2012 (6) 42 0.51 (0.8343) 41 0.24 (0.8237) 25.8 % 0.27 [ -0.09, 0.63 ]
Subtotal (95% CI) 42 41 25.8 % 0.27 [ -0.09, 0.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Total (95% CI) 111 103 100.0 % 0.55 [ 0.17, 0.93 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 10.74, df = 5 (P = 0.06); I2 =53%
Test for overall effect: Z = 2.84 (P = 0.0045)
Test for subgroup differences: Chi2 = 1.61, df = 1 (P = 0.20), I2 =38%
-2 -1 0 1 2
Favours usual care Favours CBT
to 0.90)
(1) Deshmukh data were calculated from individual patient data on a poster graph provided by the study authors.
(2) Change from baseline. 8 week endpoint.
(3) Endpoint scores at end of treatment (3 months). 6 month follow up also available and reported narratively.
(4) Endpoint scores. Post 8 week treatment, or pre-treatment in control (8 weeks after baseline and before controls started treatment)
(5) Change from baseline, 16 weeks
(6) Change from baseline. 10 week endpoint (6 and 12 month follow-up data reported narratively). Absolute scores were also reported and changed the pooled result
to MD 0.42, 95% CI -0.06
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A D D I T I O N A L T A B L E S
Table 1. Summary of study characteristics
Study N Country
(centres)
Asthma Psychology CBT Outcome
time points
Format Mean age
Deshmukh
2008
18 Australia (un-
clear)
NR “with
anxiety”
4 sessions 1.2 months
EoT
3 months FU
Group NR
Grover 2002 10 India (1) NR NR 15 sessions Unclear Individual NR
Grover 2007 40 India (1) 2+ years diag-
nosis
Those medi-
cated or with
psychiatric
history
excluded.
15 sessions of
1 h
1.5 to 2
months EoT
Individual NR
Parry 2012 94 UK (16) “clinical diag-
nosis”
“highly anx-
ious” as per
HADS-A or
ASC-PF cut-
offs
1.5 h intro
4 to 6 sessions
of 1 hour
± 2 follow-up
sessions
1.5 to 3
months EoT
6 months FU
Individual 43.4
Pbert 2012 83 USA (1) NIH/
NHLBImild-
severe persis-
tent
Those medi-
cated or with
psychiatric
history
excluded.
8 sessions of
2.5 hours + 6-
hour session
2.5 months
EoT
6 and 12
months FU
Group 52.7
Put 2003 23 Belgium (1) Diagno-
sis for at least
6 months
NR 6 sessions of 1
hour
3 months
EoT
6 months FU
Individual 45.5
Ross 2005 48 Canada (un-
clear)
Under spe-
cialist care/re-
cent attack
Panic
disorder diag-
nosis, 3 recent
attacks
12 sessions of
1.5 hours
2 months
EoT
6 months FU
Group 39.0
Sommaruga
1995
40 Italy (1) Diagnosed,
treated,
and followed
up according
to ATS guide-
lines
NR 6 educational
sessions (2 in
and 4 out
of hospital), 3
CBT sessions
+ 6 physician
visits
12 months af-
ter discharge
Individual 47.5
Yorke 2013 51 UK (2) Severe refrac-
tory asthma (
ATS 2000)
and BTS
HADS anxi-
ety or depres-
sion > 8
8 sessions of
1.5 h
4 months FU Group NR
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Table 1. Summary of study characteristics (Continued)
Steps 4 and 5
care
ASC-PF = Asthma Symptom Checklist Panic-Fear subscale; ATS = American Thoracic Society; BTS = British Thoracic Society; CBT
= cognitive behavioural therapy; EoT = end of treatment; FU = follow-up; HADS-A = Hospital Anxiety and Depression Scale,
Anxiety scale; NIH/NHLBI = National Institutes of Health/National Heart, Lung, and Blood Institute; NR = not reported
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
Electronic searches: core databases
Database Frequency of search
CENTRAL (Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
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(Continued)
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE (Ovid) search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
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Note: The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials in the Cochrane Airways Group Specialised
Register
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Behavior Therapy Explode All
#6 MeSH DESCRIPTOR Psychotherapy
#7 CBT:TI,AB,KW
#8 cognitiv* NEAR3 (behav* or treatment* or technique* or therap* or intervention* or restructur* or reappraisal*)
#9 behav* NEAR3 (treatment* OR therap* or intervention* OR activat* or technique* or modif* or change*)
#10 coping* NEAR3 (skill* or strateg*)
#11 psychotherap*
#12 psychological*
#13 talk* NEAR3 (therap* or intervention*)
#14 anxiety or anxious*
#15 panic*
#16 stress*
#17 depress*
#18 mood*
#19 mindful*
#20 acceptance* NEAR commitment*
#21 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 OR #17 OR #18 OR #19 OR #20
#22 #4 and #21
[Note: In search line #1, MISC1 denotes the field in which the reference has been coded for condition, in this case, asthma]
C O N T R I B U T I O N S O F A U T H O R S
KK: background and methods, sifting search results, data extraction, risk of bias, data analysis, GRADE, results write-up, discussion.
MN: input in background and methods, sifting search results and inclusion/exclusion decisions, data extraction, risk of bias, discussion.
VD: sifting search results and inclusion/exclusion decisions, data extraction, risk of bias, abstract and plain language summary.
JY: inclusion/exclusion decisions, GRADE checking, discussion.
D E C L A R A T I O N S O F I N T E R E S T
Kayleigh Kew: none known.
Marina Nashed: none known.
Valdeep Dulay: none known.
Janelle Yorke is the primary author of one of the included studies. Data extraction and ’Risk of bias’ judgements were completed by
the other review authors.
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S O U R C E S O F S U P P O R T
Internal sources
• Kayleigh Kew, UK.
Supported by St George’s, University of London
External sources
• National Institute for Health Research, UK.
Evidence to guide care in adults and children with asthma, 13/89/14
This project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure, Cochrane
Programme Grant or Cochrane Incentive funding to the Airways Group. The views and opinions expressed therein are those of the
authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS, or the Department of Health.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Valdeep Dulay joined the author team after the protocol was published and contributed to the screening of abstracts, ’Risk of bias’
judgements, and data extraction along with KK and MN as planned, so his initials have been added.
We had planned for one review author (KK) to extract study characteristics, but this was also done by a second review author (MN or
VD) in order to reduce bias and potential for error.
We were unable to pool more than 10 studies, and so could not create and examine a funnel plot to explore possible small-study and
publication biases as planned in the protocol.
We planned to conduct subgroup analyses on the three primary outcomes: asthma-related quality of life, exacerbations requiring at
least a course of oral steroids, and asthma control. While we did not specify a minimum number of studies to conduct the subgroup
analyses, only three studies contributed data to the second and third primary outcomes, which we did not consider to be sufficient for
subgroup analyses. As such, we conducted subgroup analyses on the asthma-related quality of life outcome only.
We added a justification for the two primary outcomes on the recommendation of a peer referee, and explained the reasoning behind
the omission of an ’adverse events’ outcome. We also added more detail to the inclusion criteria relating to the control groups (usual
care or a minimal-intervention control group) due to uncertainty that arose when deciding whether to include or exclude studies. We
removed the comparator ’versus usual care’ from the title due to variation in the control groups among studies (no treatment, waiting
list, etc.).
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